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Abstract 
 
 
Camptothecin analogs such as topotecan are currently tested in clinical trials for 
brain tumors. However the clinical outcome is far below the expectations, which are 
derived from the promising preclinical studies. This discrepancy could be partially 
attributed to the presence of two barrier systems in the brain, the blood brain barrier 
(BBB) and blood cerebrospinal fluid (CSF) barrier (BCB). Further investigations have 
demonstrated multiple ATP-binding cassette (ABC) transporters are present at the two 
barriers. Camptothecin analogs are well known substrates for several of the transporters. 
This work defined the role of two ABC transporters, Bcrp1 and P-gp in determination of 
topotecan CNS penetration in mouse models by using cerebral microdialysis.  
 
Microdialysis sampling of drugs in ventricular cerebrospinal fluid (vCSF) 
provides insight into drug penetration into the brain across the blood CSF barrier (BCB); 
however, this method has been reported primarily in larger animal species. The initial 
studies were designed to improve our existing surgical technique to implant a 
microdialysis cannula into the lateral ventricle to sample vCSF. The modifications done 
in these studies consisted of changes in the stereotaxic coordinates and insertion of the 
cannula at a 20° angle.  Exact placement of the probe was confirmed using ultrasound 
(US), micro-computed tomography (CT), and histologic review of serial paraffin 
sections.  Studies of topotecan CSF penetration in the FVB mouse using this modified 
approach determined that the vCSF to plasma AUC ratio of unbound topotecan lactone 
was greater than that previously reported using previous surgical technique.  
 
Results of studies from this lab have shown that topotecan has differential CNS 
penetration, and that vCSF topotecan penetration is greater than penetration into brain 
parenchymal extracellular fluid (ECF). We hypothesize Bcrp1 and P-gp together play a 
major role in regulation of topotecan CNS penetration. To further characterize the 
topotecan CNS transport mechanisms, topotecan penetration in two CNS compartments, 
vCSF and brain parenchymal ECF were determined in several knockout mouse models 
(Bcrp1(-/-), Mdr1a/b(-/-) and Bcrp1/Mdr1a/b(-/-)) by adapting an intracerebral microdialysis 
technique. After an intravenous (i.v.) bolus dose of 4 mg/kg topotecan, unbound 
topotecan lactone vCSF penetration was defined by a vCSF to plasma area under the 
curve ratio (AUCu,vCSF/AUCu,plasma). The topotecan vCSF penetration 
(AUCu,ECF/AUCu,plasma) was significantly decreased in all three knockout models 
compared with wild type. The penetration into the brain parenchyma, defined by the ECF 
to plasma AUC ratio, was not changed in Bcrp1(-/-) but significantly increased in 
Bcrp1/Mdr1a/b(-/-). Pre-treatment with the EGFR tyrosine kinase inhibitor gefitinib (200 
mg/kg) to inhibit Bcrp1 and P-gp transporters significantly decreased topotecan vCSF 
penetration but increased ECF penetration in FVB wild type. The topotecan lactone to 
carboxylate AUC ratio in vCSF (AUClactone,CSF/AUCcarboxylate,CSF) was calculated in FVB 
wild type and three knockout models. Interestingly, a preferential disposition of 
topotecan lactone over carboxylate was apparent in vCSF of wild type, Bcrp1(-/-) and 
Mdr1a/b(-/-) but not in Bcrp1/Mdr1a/b(-/-). These studies are the first to carefully assess the 
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contribution of efflux transporters to topotecan penetration into brain ECF and vCSF, and 
to assess the importance of lactone compared with carboxylate. 
 
Whereas these studies have all been conducted in a non-tumor bearing model, we 
evaluated the effect of the presence of a primary CNS tumor on topotecan CNS 
penetration. An orthotopic human glioblastoma (luciferase labeled U-87) mouse model 
was constructed. Preliminary intratumoral microdialysis studies have not found different 
topotecan disposition in tumor from normal brain. However, the model might be biased 
due to the position of tumor inoculation and will require further study for clarification. 
 
In conclusion, our findings suggest ABC transporters, Bcrp1 and P-gp, play a 
major role in topotecan CNS penetration by enhancing topotecan penetration into vCSF 
and restricting penetration into ECF. This insight can be translated in clinical studies to 
improve topotecan CNS penetration. 
 
 
 v
Table of Contents 
 
 
Chapter 1. Introduction ........................................................................................................1 
1.1 Primary CNS tumors: incidence and treatment .............................................................1 
1.1.1    Incidence of primary CNS tumors .....................................................................1 
1.1.2    Treatment for primary CNS tumors in children.................................................2 
1.2 Chemotherapy for primary CNS tumors........................................................................2 
1.2.1    Conventional chemotherapy ..............................................................................2 
1.2.2    Camptothecin analogs........................................................................................4 
1.3 Blood brain barrier (BBB) and blood CSF barrier (BCB).............................................8 
1.3.1    Blood brain barrier.............................................................................................9 
1.3.2    Blood cerebrospinal fluid barrier .....................................................................11 
1.4 The effect of ABC transporters on camptothecin analogs CNS penetration ...............12 
1.4.1    The role of ABC transporters in vitro studies..................................................14 
1.4.2    The utilization of targeted mutation mouse models of ABC transporters .......15 
1.5 Methods to evaluate CNS drug penetration .................................................................16 
1.5.1    Homogenization and autoradiography method................................................16 
1.5.2    Microdialysis....................................................................................................16 
1.5.3    Pharmacokinetic considerations.......................................................................18 
1.5.4    Modulation of ABC transporters by 4-anilinoquinazolines.............................20 
1.6 Blood brain tumor barrier (BTB).................................................................................21 
1.6.1    The factors affecting BTB ...............................................................................21 
1.6.2    Early studies on drug penetration in the brain tumors .....................................24 
1.6.3    In vivo microdialysis studies on drug penetration through BTB.....................25 
1.7 Summary ......................................................................................................................26 
1.8 Objectives ....................................................................................................................27 
 
Chapter 2. A Modified Surgical Procedure for Microdialysis Probe Implantation in 
the Lateral Ventricle of an FVB Mouse...........................................................28 
2.1 Introduction..................................................................................................................28 
2.2 Materials and methods .................................................................................................29 
2.2.1    Drugs................................................................................................................29 
2.2.2    Animals ............................................................................................................29 
2.2.3    Stereotaxic coordinates calculation and adjustment ........................................29 
2.2.4    Cranial surgery.................................................................................................30 
2.2.5    Ultrasound imaging..........................................................................................30 
2.2.6    Micro-CT analysis ...........................................................................................33 
2.2.7    Histology..........................................................................................................33 
2.2.8    Microdialysis study in vCSF of FVB mice......................................................34 
2.2.9    Microdialysis probe recovery ..........................................................................34 
2.2.10  Noncompartmental analysis of vCSF pharmacokinetic data ...........................34 
2.2.11  Compartmental analysis of plasma pharmacokinetic data...............................35 
2.2.12  Statistical analysis............................................................................................35 
 
 
 vi
2.3 Results..........................................................................................................................35 
2.3.1    Determination of stereotaxic coordinates ........................................................35 
2.3.2    Ultrasound imaging study................................................................................37 
2.3.3    Micro-CT imaging analysis .............................................................................37 
2.3.4    Topotecan penetration through blood CSF barrier in FVB mice.....................37 
2.4 Discussion ....................................................................................................................39 
 
Chapter 3. Penetration of Topotecan Lactone across Blood-Brain Barrier and Blood-
CSF Barrier: Differential Role of P-Glycoprotein (P-gp) and Breast 
Cancer Resistance Protein (BCRP)..................................................................43 
3.1 Introduction..................................................................................................................43 
3.2 Materials and methods .................................................................................................44 
3.2.1    Drugs and chemicals ........................................................................................44 
3.2.2    Animals ............................................................................................................45 
3.2.3    Topotecan plasma protein binding...................................................................45 
3.2.4    Brain surgery....................................................................................................45 
3.2.5    Microdialysis in ventricular CSF and brain ECF.............................................46 
3.2.6    Microdialysis probe recovery ..........................................................................46 
3.2.7    Noncompartmental analysis of brain topotecan data .......................................46 
3.2.8    Topotecan plasma pharmacokinetics ...............................................................47 
3.2.9    Three-compartment analysis of combined plasma and brain lactone 
pharmacokinetic data .......................................................................................48 
3.2.10  Three-compartment analysis of plasma topotecan lactone and carboxylate 
data...................................................................................................................48 
3.2.11  Immunohistochemistry ....................................................................................49 
3.2.12  In vitro study of effect of pH on topotecan lactone and carboxylate 
transport by BCRP ...........................................................................................49 
3.2.13  Statistical analysis............................................................................................49 
3.3 Results..........................................................................................................................50 
3.3.1    Topotecan lactone protein binding...................................................................50 
3.3.2    Bcrp1 and P-gp enhance topotecan penetration into ventricular CSF .............50 
3.3.3    Bcrp1 and P-gp decrease topotecan penetration into brain ECF .....................54 
3.3.4    Differential regulatory effects of gefitinib on topotecan penetration into 
vCSF and ECF .................................................................................................54 
3.3.5    Preferential disposition of topotecan lactone in vCSF.....................................54 
3.3.6    Saos2-BCRP cells preferentially transport topotecan lactone .........................58 
3.4 Discussion ....................................................................................................................58 
 
Chapter 4. Topotecan Penetration in an Intracranial Human Glioblastoma (U-87) 
Mouse Model ...................................................................................................64 
4.1 Introduction..................................................................................................................64 
4.2 Methods and materials .................................................................................................65 
4.2.1    Drugs and reagents...........................................................................................65 
4.2.2    Tumor cell line.................................................................................................65 
4.2.3    Animal..............................................................................................................65 
4.2.4    Intracranial tumor inoculation..........................................................................66 
 vii
4.2.5    Microdialysis guide cannula implant ...............................................................66 
4.2.6    Bioluminescence imaging................................................................................66 
4.2.7    Correlation of tumor growth with bioluminescence signal..............................67 
4.2.8    Microdialysis procedure...................................................................................67 
4.2.9    Histology..........................................................................................................67 
4.2.10  Noncompartmental analysis of brain pharmacokinetic data............................68 
4.2.11  Protein binding.................................................................................................68 
4.2.12  Compartmental analysis of plasma pharmacokinetic data...............................68 
4.2.13  Statistical analysis............................................................................................69 
4.3 Results..........................................................................................................................69 
4.3.1    Topotecan lactone protein binding...................................................................69 
4.3.2    Tumor volume correlated to bioluminescence signal ......................................69 
4.3.3    Topotecan penetration is not statistically different in the U-87 tumor tissue 
from normal tissue ...........................................................................................69 
4.4 Discussion ....................................................................................................................74 
 
Chapter 5. Summary and Future Directions ......................................................................76 
  
List of References ..............................................................................................................80 
 
Appendix: Analysis of Topotecan Clearances across BCB or BBB................................103  
 
Vita...................................................................................................................................105 
 viii
List of Tables 
 
 
Table 2-1  vCSF to plasma AUC ratios of unbound topotecan lactone at the 
presence or absence of gefitinib.................................................................40 
 
Table 3-1  Noncompartmental (AUC ratio) and compartmental analysis 
(CLin/CLout) for brain (CSF or ECF) to plasma AUC ratio of 
unbound topotecan lactone in various mouse models................................53 
 
 ix
List of Figures 
 
 
Figure 1-1  Structures of camptothecin analogs. ............................................................5 
 
Figure 1-2  Blood brain barrier.....................................................................................10 
 
Figure 1-3  Blood cerebrospinal fluid barrier. ..............................................................13 
 
Figure 1-4  General two-compartment model for drug transport between plasma 
and brain.....................................................................................................19 
 
Figure 1-5  Blood endothelial cells in normal or tumor tissues....................................23 
 
Figure 2-1  Schematic demonstration of sterotaxic coordinates calculation. ...............31 
 
Figure 2-2  Ultrasound imaging study. .........................................................................32 
 
Figure 2-3  H&E staining of sagittal brain section after probe insertion......................36 
 
Figure 2-4  MicroCT analysis of intact head and excised brain following MicroFil 
infusion. .....................................................................................................38 
 
Figure 3-1  Microdialysis probe track in lateral ventricle or parenchymal tissue. .......51 
 
Figure 3-2  Topotecan lactone penetration into vCSF in various mouse models at 
one dose of topotecan 4mg/kg i.v. bolus....................................................52 
 
Figure 3-3  Topotecan lactone penetration into brain ECF in various mouse 
models at one dose of topotecan 4mg/kg i.v. bolus. ..................................55 
 
Figure 3-4  Regulatory effect of gefitinib on topotecan penetration into brain ECF 
or vCSF at one dose of topotecan 4mg/kg i.v. bolus and gefitinib 
200mg/kg oral gavage pretreatment...........................................................56 
 
Figure 3-5  vCSF lactone to carboxylate AUC ratio of unbound topotecan. ...............57 
 
Figure 3-6  pH effect on topotecan lactone and carboxylate transport by BCRP.........59 
 
Figure 3-7  IHC staining of Bcrp in FVB and Mdr1a/b(-/-). ..........................................62 
 
Figure 4-1 Tumor (U-87) growth monitored by bioluminescence ..............................70 
 
Figure 4-2 Correlation of tumor volume to bioluminescence signal...........................71 
 
Figure 4-3 Microdialysis probe in tumor or normal brain...........................................72 
 x
Figure 4-4 TPT penetration in the U-87 tumor model of CD-1 nude mice.................73 
 
 
 xi
List of Abbreviations 
 
 
ABC transporters ............................. Adenosine triphosphate-binding cassette transporters 
aCSF................................................................................................................Artificial CSF 
ATP..................................................................................................Adenosine triphosphate 
AUC ......................................................................Area under the concentration-time curve 
BBB.........................................................................................................Blood-brain barrier 
BCB...................................................................................Blood-cerebrospinal fluid barrier 
BCRP ..................................................................................Breast cancer resistance protein 
BMS-354825............................................................................................Dasatinib, Sprycel 
BTB..............................................................................................Blood-brain tumor barrier 
CL ..........................................................................................................................Clearance 
cLogP ...........................................................................................................calculated LogP 
CNS..................................................................................................Central nervous system 
COG ..........................................................................................Children’s Oncology Group 
CPTs...............................................................................................................Camptothecins 
CSF ........................................................................................................ Cerebrospinal fluid 
DMSO.....................................................................................................Dimethyl sulfoxide 
ECF .......................................................................................................... Extracellular fluid 
EDT.......................................................................................... Exposure duration threshold 
EGFR/Erbb1 .................................................................... Epidermal growth factor receptor 
GF120918 ...............................................................................................................Elacridar 
GW572016................................................................................................Lapatinib, Tykerb 
IFP.................................................................................................. Interstitial fluid pressure 
ILs ...................................................................................................................... Interleukins 
IRN..................................................................................... Iirinotecan, CPT-11, Camptosar 
LogP.......................................................................................................Partition coefficient 
LTC4.............................................................................................................Leukotriene C4 
MMPs...........................................................................................Matrix metalloproteinases 
MRP ......................................................................................... Multidrug resistance protein 
MTT ....................................4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide 
NONMEM .......................................................................Nonlinear mixed-effect modeling 
OATs...........................................................................................Organic anion transporters 
OATPs...................................................................Organic anion transporting polypeptides 
OCTs ..........................................................................................Organic cation transporters 
OS ................................................................................................................Overall survival 
OSI-774.................................................................................................... Erlotinib, Tarceva 
PBS ..............................................................................................Phosphate-buffered saline 
PFS.................................................................................................Progression free survival 
P-gp ...................................................................................................P-glycoprotein, MDR1 
PNET...............................................................................Primitive neuroectodermal tumors 
POG............................................................................................. Pediatric Oncology Group 
PSC833 ................................................................................................................. Valspodar 
RTKs ............................................................................................ Receptor tyrosine kinases 
SLC ...................................................................................................... Solute carrier family 
 xii
 xiii
STI-571 .....................................................................................................Imatinib, Gleevec 
TGF-β................................................................................... Transforming growth factor- β 
TJ.....................................................................................................................Tight junction 
TK ................................................................................................................ Tyrosine kinase 
TKI................................................................................................ Tyrosine kinase inhibitor 
TPT .......................................................................................................................Topotecan 
TPT C................................................................................................Topotecan carboxylate 
TPT L ....................................................................................................... Topotecan lactone 
vCSF .................................................................................... Ventricular cerebrospinal fluid 
VEGF .............................................................................Vascular endothelial growth factor 
ZD1839 ........................................................................................................Gefitinib, Iressa 
ZD6474 ................................................................................................Vandetanib, Zactima 
4-AQ .................................................................................................. 4-aninlinoquinazoline 
 
Chapter 1. Introduction   
 
 
1.1 Primary CNS tumors: incidence and treatment 
 
 
1.1.1    Incidence of primary CNS tumors 
 
The American Cancer Society estimates 20,500 new cases of primary brain and 
other nervous system tumors will be diagnosed in the United States in 2007.  They also 
estimate that over 12,000 patients will die from these tumors (Jemal et al., 2007).  Central 
nervous system (CNS) tumors are the most common solid malignancy in children with an 
estimated 3,200 children diagnosed with primary CNS tumors in 2007(American Cancer 
Society, 2007).  According to a recent report by the Centers for Disease Control and 
Prevention (CDC), CNS tumors were the second leading cause of death in persons aged 
1-19 years in the United States accounting for 25% of total cancer deaths (Centers for 
Disease Control and Prevention, 2007). In the United States, although the annual 
mortality rate of pediatric cancers has steadily decreased over the past two decades, the 
proportion of deaths from CNS tumors in the same population has increased from 18% to 
30% (Gururangan and Friedman, 2004). Worldwide, approximately 30,000-40,000 
children develop CNS tumors each year, and the majority of them do not survive despite 
aggressive therapy (Bleyer, 1999; Fisher et al., 2007).  
 
CNS tumors are classified mainly by location and histopathology into the 
following groups: Gliomas (including astrocytoma (grade II), anaplastic astrocytoma 
(grade III), glioblastoma (grade IV) and other gliomas), primitive neuroectodermal 
tumors (PNETs), medulloblastoma, meningioma, germ cell tumors and tumors at sellar 
region (including pituitary tumors and craniopharyngioma) (Fisher et al., 2007). In adults 
gliomas are the most common CNS tumors in which glioblastoma multiforme (GBM), 
the most malignant glioma, is the primary histological type. Other frequent adult CNS 
tumors include meningiomas and brain metastasis mainly from lung and breast cancers 
(Nguyen and DeAngelis, 2007).  
 
In children, low grade astrocytomas are the most common CNS tumors 
comprising more than 50% of total pediatric CNS tumors  then followed by 
medulloblastoma (16%) and glioblastoma (7%) (Ullrich and Pomeroy, 2003; Gururangan 
and Friedman, 2004). Originating from neuroepithelial tissue, most gliomas are located in 
brain parenchymal tissue and are perfused by capillaries in the brain. However 
medulloblastoma, now recognized as a molecularly distinct tumor from PNET, is located 
in cerebellum and has direct access to cerebrospinal fluid (CSF) (Pomeroy et al., 2002). 
Tumor location, along with other properties (e.g. tumor size, tumor genetics), serve as 
important prognostic factors (Fisher et al., 2007) as well as treatment option 
considerations.   
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1.1.2    Treatment for primary CNS tumors in children 
 
Currently three treatment modalities are available for pediatric CNS tumors, 
surgical resection, radiation therapy, and chemotherapy. In most cases, surgical resection 
is the first option. Surgery alone or combined with radiation therapy may cure many 
tumors, including some cerebellar astrocytomas, ependymomas, meningiomas, and some 
low-grade gliomas (Stieber and Mehta, 2007; Asthagiri et al., 2007; Young, 2007). 
Children with high grade tumors, such as anaplastic astrocytomas are not cured by 
surgery alone. Surgery however will reduce the amount of tumor that remains to be 
treated by radiation or chemotherapy. Moreover patients with diseases with specific 
histopathological properties (e.g., infiltrating gliomas mixed with critical cortical 
functional regions) cannot be treated with surgery and require other therapies (Asthagiri 
et al., 2007). Radiation therapy also plays a primary role in management of most 
malignant and many benign CNS tumors (Stieber and Mehta, 2007). Since high doses of 
radiation can damage normal brain tissue, techniques (e.g., stereotaxic radiosurgery) have 
been developed to precisely target tumor tissues and spare normal tissues. The exception 
to this is patients younger than 3 years of age. Because the brain of a child is still 
growing, radiation may severely impair neurocognitive capabilities. Although rare, 
radiation may cause DNA damage which may lead to a secondary malignancy (e.g., 
meningiomas) (Stieber and Mehta, 2007; Al-Mefty et al., 2004). Chemotherapy is 
generally used for high-grade tumors and may be given before or after surgery and 
radiation therapy. The treatment for children under 3 years old usually relies mainly on 
chemotherapy after surgery (American Cancer Society, 2007). The goal of chemotherapy 
is to further prolong survival after surgery and radiation, and maintain the quality of 
life(Castro et al., 2003).  
 
 
1.2 Chemotherapy for primary CNS tumors 
 
 
1.2.1    Conventional chemotherapy 
 
Drug treatment for brain tumors in children and adults began to take form in the 
early 1970s, when clinical benefits were observed from nitrosoureas in adult malignant 
gliomas (Finlay, 1999). At the same time, vincristine and nitrosoureas were also reported 
to have activity in recurrent childhood brain tumors (Finlay, 1999). When radiotherapy 
had been recognized to cause irreversible damage to the brain of young children, 
chemotherapy became an important treatment option. Conventional chemotherapy 
usually included multiple drugs from nitrosoureas (e.g., lomustine), mitotic spindle 
inhibitors (e.g., vincristine), alkylating agents (e.g., melphalan), platinum complexes 
(e.g., cisplatin), antimetabolites (e.g., methotrexate) and glucocorticoids (e.g., 
dexamethasone). Different combinations of these types of drugs were tested in clinical 
trials. In addition to these conventional agents, drugs with novel mechanisms (e.g., 
camptothecin analogs, temozolomide, and O6-benzylguanine etc.) have been introduced 
to adjuvant chemotherapies (Broniscer et al., 2007; Lamers et al., 2008; Stewart et al., 
2004a). 
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Medulloblastoma is the most common malignant pediatric solid tumor. Based on 
tumor size and location, medulloblastoma can be classified in stages with increasing risk 
from T1 to T4. Alternatively it can also be classified from M0 to M4 with increasing risk 
of metastasis. Standard therapy for children with medulloblastoma consists of maximal 
surgical resection followed by craniospinal irradiation combined with adjuvant 
chemotherapy. Early clinical studies were conducted by multiple groups, including 
Children’s Cancer Group (CCG) (Evans et al., 1990), International Society of Pediatric 
Oncology (SIOP) (Tait et al., 1990) and Pediatric Oncology Group (POG) (Krischer et 
al., 1991). The results were similar with a long term survival rates of approximately 55% 
at 5 years and 45% at 10 years. However the survival rates were poorer (46% at 5 years) 
for patients diagnosed with both high T (T3 or T4) and M (M1 through M3) stage disease 
(Gajjar et al., 2006).  Patients who received post-operative adjuvant radiotherapy and 
chemotherapy had a significant survival advantage over those who received radiotherapy 
alone (Robertson, 2006). Over the last decade, the continuously improved therapy 
resulted in the five year progression free survival rate of approximately 80% for patients 
with average-risk disease and 60% for patients with high-risk disease (Merchant et al., 
2007; Gajjar et al., 2006; Packer et al., 2006; Gottardo and Gajjar, 2006). 
 
Adjuvant chemotherapy has also been a common modality for glioma treatment. 
Chemotherapy with a combination of multiple agents (e.g. procarbazine, lomustine, 
vincristine) have improved the quality of life in adult patients with malignant 
astrocytomas (Taphoorn et al., 2007; Rabbani et al., 2007). However the clinical benefits 
were not consistently observed in pediatric patients.  In an early high grade astrocytoma 
trial from Children’s Cancer Study Group, five-year event-free survival was seen in 46% 
of patients in the radiotherapy and chemotherapy group, and only 18% of patients in the 
radiotherapy-alone group (Sposto et al., 1989).  In a recent Pediatric Oncology Group 
(POG) study, 40 patients with high grade gliomas were treated with radiotherapy and 
adjuvant chemotherapy (procarbazine or topotecan). The 3-year OS and PFS were only 
15% and 10%, respectively (Chintagumpala et al., 2006). In a Children’s Oncology 
Group (COG) study, 113 patients with CNS tumors were treated with temozolomide the 
dosage of which was based on prior radiation treatment status. Among 75 glioma 
patients, only 1 partial response was observed. This is in contrast to 1 complete response 
and 3 partial responses out of 29 medulloblastoma patients (Nicholson et al., 2007). In a 
recent trial in children with high grade astrocytoma, with a total of sixteen patients 
enrolled, five year PFS was 28.6% (Sanders et al., 2007). These studies suggest effective 
chemotherapy for pediatric glioma patients is still lacking. 
 
In summary, the role of conventional chemotherapy in pediatric brain tumor 
treatment is very uncertain. Although a portion of medulloblastoma patients have 
benefited from conventional chemotherapy to some degree, such similar benefits have not 
been observed in high grade astrocytoma patients. Treatment failure is multi-factorial and 
can be attributed to issues such as intrinsic tumor resistance or to therapy related issues 
such as optimal dosing strategy or optimal drug delivery failure. Although each of these 
aspects warrants further investigation, novel agents are still urgently needed.  
 
 3
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1.2.2    Camptothecin analogs 
 
The camptothecin analogs are a promising group of novel agents that have shown 
wide antitumor activity.  The anti-tumor activity of the parent 20(S)-camptothecin, a 
natural alkaloid from the Chinese tree Camptotheca acuminata, was first described in the 
1960s (Wall and Wani, 1977; Kepler et al., 1969)  The natural compound, however, 
demonstrated unpredictable toxicities in clinical trials including hemorrhagic cystitis 
(Hertzberg et al., 1989; Wall and Wani, 1977). The conversion of the open carboxylate 
form into the closed lactone form at the acidic pH of bladder was considered to be 
responsible for the severe hemorrhagic cystitis, which could be life-threatening (Lansiaux 
et al., 2007). Different strategies were developed to modify the compound to stabilize the 
closed lactone form and reduce the adverse reactions.  Currently only two camptothecin 
analogs, topotecan and irinotecan, have been approved by Food and Drug Administration 
(FDA) for clinical use.  Topotecan is indicated for small cell lung cancer and metastatic 
ovarian cancer after failure of first-line chemotherapy (Kudelka et al., 1996; Lynch, Jr. et 
al., 1994).  Irinotecan is indicated for metastatic colorectal cancer usually with other 
drugs (Rothenberg et al., 1996; Sasaki et al., 1994; Shimada et al., 1993). As a prodrug, 
irinotecan is converted by carboxylesterase to its active metabolite SN-38 in vivo.  
 
The ester bond of the lactone E ring of camptothecin analogs (Figure 1-1) 
undergoes a reversible pH-dependent hydrolysis, with a closed-lactone ring form at acidic 
conditions and open-carboxylate ring form at basic conditions. Under physiological 
conditions (pH 7.2-7.4) the carboxylate form predominates. However only the lactone 
form of these compounds is responsible for their biological activity to interact with the 
topoisomerase-I and DNA complex (Hertzberg et al., 1989; Capranico et al., 2007; 
Marchand et al., 2006). The structures of topotecan and irinotecan and pH-dependent 
conversions are shown in Figure 1-1. 
 
1.2.2.1  Preclinical studies of topotecan and irinotecan for brain tumor  
         treatment 
 
In rodent models of pediatric brain tumors, both topotecan and irinotecan showed 
potent anti-brain tumor activities (Friedman et al., 1994; Hare et al., 1997; Pawlik et al., 
1998; Zamboni et al., 1998). The activity of topotecan was evaluated against a panel of 
xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade 
gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and 
medulloblastomas (D425 Med) growing subcutaneously (s.c.) in athymic nude mice. 
Topotecan was given at a dose of 1.9 mg/kg by intraperitoneal (i.p.) on days 1-5 and 8-
12, which represents the dose lethal to 10% of treated animals. Topotecan was active in 
the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-
54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor 
regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor 
regressions were seen in any control animal (Friedman et al., 1994). This study 
demonstrated topotecan was effective against CNS tumors implanted as s.c. xenografts in 
mice. 
 
 
 R1 R2 R3 R4 
Topotecan H OH -CH2N(CH3)2 H 
Irinotecan H H -CH2CH3 
SN-38 H OH H -CH2CH3 
 
 
Figure 1-1  Structures of camptothecin analogs. 
 
Chemical structures of camptothecin analogs and pH dependent conversion between 
lactone and carboxylate forms. At acidic conditions the lactone form dominates; at basic 
conditions the carboxylate dominates.
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Houghton and colleagues studied the efficacy of topotecan and irinotecan against 
a panel of 21 human tumor xenografts from adult and pediatric malignancies. Many of 
the xenografts represented sublines resistant to conventional chemotherapy. All tumors 
were grown subcutaneously. Topotecan was administered by oral gavage 5 days per week 
for 12 consecutive weeks at dosages up to 1.5mg/kg. Irinotecan was given by i.v. 
administration daily for 5 days each week for 2 weeks [(d x 5)2] (one cycle of therapy), 
repeated every 21 days at the dosage up to 10mg/kg maximum tolerated dose. A pediatric 
glioblastoma line (SJG-2) had a 100% complete response (CR) to irinotecan and 80% CR 
to topotecan. A pediatric medulloblastoma line had a 100% CR to topotecan and 88% CR 
to irinotecan (Houghton et al., 1995). This study demonstrated both topotecan and 
irinotecan had outstanding anti-tumor activities in various human tumor xenografts 
including CNS tumors. 
 
The promising anti-tumor activity of camptothecin analogs were further 
confirmed in other CNS tumor models. Hare and colleagues reported irinotecan induced 
complete response in two brain tumor (D456 high grade glioma, D341 medulloblastoma) 
s.c. xenografts in athymic mouse models when irinotecan was given at a dosage of 40 
mg/kg via intraperitoneal injection on days 1-5 and 8-12 (Hare et al., 1997). Compared 
with more than 40 conventional drugs tested including alkylators, antimetabolites, vinca 
alkaloids, anthracyclines, and L-asparaginase (Friedman et al., 1983; Friedman et al., 
1986), irinotecan has demonstrated the most potent anti-CNS tumor activity. Vassal et al. 
evaluated irinotecan in 5 advanced stage subcutaneous medulloblastoma xenografts in 
nude mice. With a 5-day dosing schedule, the highest i.v. dose (40 mg/kg/day) induced 
complete regressions in four of five xenografts. To study the dosing schedule dependency 
of its anti-tumor activity, irinotecan was given i.v. at the same total doses over the same 
period (33 days) using either a protracted or a sequential schedule. With the protracted 
schedule, 3 out of 6 animals were tumor free on day 378. The sequential schedule failed 
to induce any CR (Vassal et al., 1997). This study suggested the efficacy of irinotecan 
might depend on dosing schedule. Nakatsu et al. tested SN-38, the irinotecan active 
metabolite, in a few CNS tumor cell lines. They demonstrated that SN-38 had strong 
antitumor effects on GB-1 and U-87MG two human glioblastoma cell lines with 
multidrug resistance phenotype (Nakatsu et al., 1997). 
 
In summary, the camptothecin analogs demonstrated potent anti-tumor activities 
in various CNS tumor cell lines and xenograft animal models. Due to the success of these 
preclinical studies, this class of compounds has been advanced to clinical trials for CNS 
tumors. 
 
1.2.2.2 Clinical studies with Camptothecin analogs for brain tumor treatment 
 
A Canadian group has conducted a phase II trial of topotecan in patients with 
malignant glioma. Topotecan (1.5 mg/m2 i.v. over 30 minutes) was given daily by 5 days 
every 3 weeks [(d x 5) x 3]. Among 31 patients enrolled, one had complete radiographic 
response, and one had partial response (PR). With this dose and schedule, topotecan 
showed modest activity in recurrent glioblastoma and anaplastic astrocytoma (Macdonald 
et al., 1996). The results were further corroborated in another phase II study in adults 
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with primary malignant glioma. With 63 patients enrolled and topotecan given at a dose 
of 2.6 mg/m2 over a 72-hour infusion weekly, only 4 PRs were observed from newly 
diagnosed glioblastoma (GBM) or anaplastic astrocytoma (AA). No response was 
observed from recurrent GBM (Friedman et al., 1999a).  These results suggest that 
topotecan has modest activity against malignant gliomas and further evaluation of its 
effectiveness is necessary when alternative schedules or combination regimens are 
available. 
 
Blaney and colleagues initiated a phase II study in pediatric patients with CNS 
tumors, including high grade gliomas, medulloblastomas, and brain stem tumors. 
Topotecan was administered as a 24-hour infusion starting from 5.5mg/m2 with 
escalation to 7.5mg/m2 in patients who did not experience dose-limiting toxicity. 
Disappointingly no CR or PR was observed. Topotecan was inactive in this group of 
patients with this dosing schedule (Blaney et al., 1996).  
 
The German Society for Pediatric Oncology and Hematology conducted a phase 
II study in which topotecan was administered orally in ice-cold orange juice with a 
starting dosage of 0.4 mg/m2/day and escalating to maximum tolerated dose. Among 32 
patients, 1 CR and 2 PR were observed. This study demonstrated that topotecan was only 
mildly effective against recurrent pediatric high-grade glioma (Wagner et al., 2004).  
 
Stewart and colleagues reported in a phase II trial of high-risk medulloblastoma 
and supratentorial primitive neuroectodermal tumor, in which topotecan dosing was 
pharmacokinetically guided to reach an exposure duration threshold (EDT) (Stewart et 
al., 2004a). Pharmacokinetic studies were conducted for each patient on day 1 to reach 
topotecan lactone area under the plasma concentration-time curve (AUC) of 120-
160ng/ml·h (Stewart et al., 2004a; Zamboni et al., 1998). Topotecan was initially 
administered as 30-minute infusion. After 10 patients were enrolled, the infusion was 
modified to a four-hour infusion (Zamboni et al., 1998). Target plasma topotecan AUC 
was achieved in 24 patients. Among 36 assessable patients, 4 had a CR and 6 had a PR 
(Stewart et al., 2004a). This study demonstrated topotecan was an effective agent against 
pediatric medulloblastoma when topotecan was administered on a pharmacokinetically 
guided dosing schedule. 
 
However, the promising results were not seen in a recent phase II pediatric high-
grade glioma study. Topotecan was given as 30-minute infusion and plasma 
pharmacokinetic studies were conducted to estimate topotecan exposure level. Of 14 
patients enrolled, no CR or PR was observed. 3-year OS is 14% and 3-year PFS is only 
7% (Chintagumpala et al., 2006).  
 
Irinotecan has also been extensively tested in clinical trials for CNS tumors. In 
phase I trials, several different dosing schedules and maximum tolerated dose (MTD) 
have been investigated. Since many brain tumor patients receive enzyme-inducing 
anticonvulsants (EIAs), which may significantly affect irinotecan clearance, the MTD of 
irinotecan was determined for patients with or without EIA treatment. In an adult 
recurrent malignant glioma trial, irinotecan was given over a 90-minute i.v. infusion 
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weekly for 4 weeks every 6 weeks. The MTD for EIA treatment group was determined to 
be 411 mg/m2/week and 117 mg/m2/week for patients without EIA (Gilbert et al., 2003). 
Prados and colleagues evaluated another dosing schedule in which irinotecan was given 
every 3 weeks (90-minute i.v. infusion). For EIA treatment group the MTD of irinotecan 
was determined to be 750 mg/m2/dose and 350 mg/m2/dose for non-EIA treatment group 
(Prados et al., 2004).  
 
However with promising results from preclinical studies and well-defined phase I 
studies, the clinical benefit from phase II studies with irinotecan for brain tumors were 
below expectations. In a phase II adult recurrent glioma trial where a weekly dosing 
schedule was used, Friedman and colleagues reported that of 60 patients enrolled, 9 PR 
were confirmed and no CR was observed (Friedman et al., 1999b). In this study, the 
patients were not dosed based on the EIA treatment status.  However when irinotecan 
was dosed on EIA treatment status in another phase II adult malignant glioma trial, of 18 
patients enrolled only 1 CR was observed (Batchelor et al., 2004). Turner and colleagues 
conducted a study in children with high risk malignant brain tumors. Irinotecan was given 
as a 90-minute i.v. infusion at a dosage of 125 mg/m2 weekly for 4 weeks every 6 weeks. 
2 CRs and 2 PRs were observed in total 22 patients (Turner et al., 2002). The every-3-
week dosing schedule has also been tested in a few phase II trials. In an adult recurrent 
malignant glioma trial, Cloughesy and colleagues reported 2 PRs out of a total 14 patients 
(Cloughesy et al., 2002). In another multi-center phase II study for adult glioblastoma, 
only 1 PR and 7 minor responses were observed out of a total 46 patients (Raymond et 
al., 2003). In an adult glioblastoma multiforme trial, all patients demonstrated progressive 
diseases (Chamberlain, 2002). Most recently Blaney and colleagues conducted a phase II 
study in pediatric solid tumor patients, which included children with recurrent primary 
CNS tumors. Among the patients with CNS tumors, responses were only observed in 
those with medulloblastomas (Bomgaars et al., 2007). 
 
In summary, although camptothecin analogs (topotecan and irinotecan) have 
demonstrated modest efficacy against brain tumors, the clinical outcomes did not 
reproduce the encouraging results seen in the preclinical studies. Several conclusions can 
be made from the results of these clinical trials. Topotecan and irinotecan were more 
effective in medulloblastoma than in gliomas (Stewart et al., 2004a; Bomgaars et al., 
2007). Clinical response of irinotecan was far below expectations, even lower than in 
some existing chemotherapies (Raymond et al., 2003). Tumors fail to respond to 
chemotherapy for many reasons, one of which appears to be drug resistance. However the 
fact that most of the preclinical models were constructed on s.c. implanted xenografts, 
which is not orthotopic for brain tumors, suggests that drug delivery to the brain of the 
patients may not be adequate.  This inadequacy may be due to the presence of blood brain 
barrier (BBB) and blood cerebrospinal fluid (CSF) barrier (BCB). 
 
 
1.3 Blood brain barrier (BBB) and blood CSF barrier (BCB) 
 
The BBB is a collective term used to describe the phenotype that regulates the 
material penetration into or out of the brain and protects the brain from endogenous or 
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xenobiotic toxins. The existence of the BBB was first described by a German 
bacteriologist Paul Ehrilich (1902) who observed that systemically injected dye stained 
all the organs of an animal except brain. The concept of the BBB was formally proposed 
by a Russian biochemist Lina Stern in 1921. The actual membrane structure of the BBB 
wasn’t demonstrated until the advent of scanning electron microscope in 1950s 
(Dempsey and Wislocki, 1955; Van, V and Clemente, 1955). Most of our understanding 
of the molecular structures and functions of the BBB has been achieved during the last 
three decades. The presence of the BCB was first described by Edwin Goldmann 
(Ehrilich’s student) in 1913 when he injected a dye into the CSF of the brain directly. 
Only the brain was stained but not the rest of the body. Since the CSF forms a distinct 
compartment from the extracellular fluid (ECF) of brain parenchymal tissue, the concept 
of the BCB should be distinguished from the BBB.  
 
The main focus of this work is to elucidate the mechanisms that control topotecan 
penetration into the brain. This discussion will primarily focus on the properties of the 
BBB or the BCB related to drug penetration.  
 
 
1.3.1    Blood brain barrier 
 
Structurally the BBB consists of multiple components. As depicted in Figure 1-2, 
at least three types of cells are involved to maintain the integrity of the BBB. The single 
layer of cerebral vascular endothelial cells, which are joined together by tight junctions, 
forms the pivotal component of the BBB (Davson and Segal, 1996). The pericytes and 
astrocytic foot process, which are closely associated with the endothelial cells, further 
strengthen the BBB (Abbott, 2005; Pardridge et al., 1986). Compared with other organs, 
the endothelial cells at the BBB have a particularly higher content of mitochondria 
suggesting active energy dependent activities (Oldendorf et al., 1977). In addition to 
providing physical support, the pericytes and astrocytes in the BBB also play regulatory 
roles (Zozulya et al., 2007; Abbott, 2002; Balabanov and Dore-Duffy, 1998). 
 
Functionally, the BBB is to maintain the homeostatic brain microenvironment by 
selectively transporting nutritional materials into the brain and excluding toxic 
metabolites or xenobiotics out of the brain.  To achieve the task, first the unique structure 
of the BBB greatly restricts paracellular diffusion. Second, compared with the vascular 
endothelia in other tissues, low pinocytotic and transcytotic activity of brain endothelial 
cells results in very limited non-specific trans-endothelial transport (Vorbrodt and 
Dobrogowska, 2003; Davson and Segal, 1996). However due to the nature of the plasma 
membrane, highly lipophilic small molecules are still allowed to diffuse through the 
endothelial cells. Third, the transport of solutes and nutrients including inorganic ions, 
sugars, amino acids, nucleic acids, and small peptides is selectively mediated by 
specialized proteins such as ATP-binding cassette (ABC) transporters and solute carriers 
(Vorbrodt and Dobrogowska, 2003; Ohtsuki and Terasaki, 2007).  
 
The carrier-mediated transport system refers to all the solute carrier (SLC) 
members that are classified into 47 families (Hediger et al., 2004). Among them, the 
 MDR1
MRP4
BCRP
MRP1
MRP5
 
 
Figure 1-2  Blood brain barrier. 
 
The specialized brain capillary endothelial cells sealed by tight junctions form the blood 
brain barrier (BBB). Brain capillary and pericytes are surrounded by a basal membrane, 
which is tightly ensheathed by the astrocytic end-feet.  ABC transporters such as 
MDR1(P-gp), MRP1, MRP4, MRP5, and BCRP are localized at the apical side of the 
endothelial cells.  
 
Source: Modified with permission. Loscher W, Potschka H, 2005. Drug resistance in 
brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6: 591-602. 
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family SLC21, the organic anion transporting polypeptides (OATP) and family SLC22 
organic anion/cation transporters (OAT/OCT) are the most important in terms of drug 
transport (Ohtsuki and Terasaki, 2007; Loscher and Potschka, 2005a). These transporters 
are not directly coupled with ATP but rather driven by electrochemical potential 
difference created by various ion gradients. Depending on the sub-cellular localization 
(apical or basolateral) on the endothelial cells these carrier-transporters can move 
substrates either into or out of the brain (Ohtsuki and Terasaki, 2007; Ito et al., 2005c). 
 
Another mechanism of transport at the BBB is mediated through the family of 
ATP-binding cassette (ABC) transporters. P-glycoprotein (P-gp/MDR1), the prototype of 
ABC transporters, is widely expressed through the body including BBB (Schinkel et al., 
1994; Thiebaut et al., 1987). Although P-gp was identified three decades ago (Juliano and 
Ling, 1976) its functional significance at the BBB wasn’t clearly demonstrated until the 
generation of the Mdr1a(-/-) mouse model (Schinkel et al., 1994). Schinkel and colleagues 
clearly have shown the Mdr1a deficient mouse was more sensitive to the neurotoxic 
pesticide ivermectin (100-fold) and anti-cancer drug vinblastine (3-fold) than wild type 
mice (Schinkel et al., 1994). After this study, the expression of ABC transporters in the 
brain was profiled in humans and rodents. Until now the ABC transporters that have been 
detected on protein level at the BBB include P-gp (MDR1), MRP1 (ABCB1), MRP4 
(ABCB4), MRP5 (ABCB5), and BCRP (ABCG2) (Ito et al., 2005c; Loscher and Potschka, 
2005b; Potschka et al., 2003; Zhang et al., 2000; Nies et al., 2004; Cordon-Cardo et al., 
1990; Rao et al., 1999) in both rodents and human. Particularly high level of both mRNA 
and protein of P-gp and BCRP were detected at BBB in human and rodents, which 
suggests they probably play a bigger role as a barrier(Cooray et al., 2002; Hori et al., 
2004; Schinkel et al., 1994). On the contrary, only low levels of mRNA were detected for 
transporters such as MRP2 and MRP3, which suggests they probably do not play a 
significant role at BBB (Zhang et al., 2000).  
 
A recent study indicated that the ABC transporters were associated with different 
cell types  at the BBB (Yousif et al., 2007) although the functional relevance of such 
expression pattern is not clear. While MRP1 and MRP5 were quite ubiquitously 
expressed through the BBB, MDR1, MRP4, and BCRP were closely associated with 
endothelial cells. MRP2 and MRP3 were closely associated with pericytes (Yousif et al., 
2007). Another feature about these transporters is they are strict efflux transporters, 
which means they only move substrates out of the cells where they are expressed. Current 
evidence has shown all the expressed ABC transporters are located at the apical side of 
BBB, which suggests they only efflux substrates from brain side into blood (Ito et al., 
2005c). 
 
 
1.3.2    Blood cerebrospinal fluid barrier 
 
The blood cerebrospinal fluid (CSF) barrier (BCB) consists of the choroid plexus 
(CP) and arachnoid membrane. Only the CP has been extensively studied for drug 
transport and metabolism (Johanson et al., 2005). In this work whenever BCB is 
mentioned, it is an expression of the choroid plexus related structure. As depicted in 
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Figure 1-3, the CP is composed of an outer layer of ependymal epithelial cells and an 
inner layer of capillary endothelial cells. The distinct feature of the BCB is the tight 
junction is absent between the endothelial cells but present between the ependymal 
epithelial cells. This feature results in a fenestrated capillary but a much less permeable 
layer of epithelial cells (Redzic and Segal, 2004). Although the choroid plexus is only 
distributed in the cerebral ventricles, the total surface area is the same order of magnitude 
as the total BBB due to the lush apical membrane microvilli (Keep and Jones, 1990).  
 
Functionally, CP serves as a secretory and metabolizing organ, which is often 
described as a mini kidney and liver of the brain (Strazielle and Ghersi-Egea, 2000). The 
total volume of CSF in human is estimated 150-270 ml, which is renewed about 5 times a 
day (Kohn et al., 1991; Davson and Segal, 1996). Furthermore the choroidal vascular 
perfusion is five to ten times that of the cerebral blood flow (Faraci et al., 1994). 85% of 
the CNS sodium chloride is secreted through choroid plexus compared with 15% through 
the BBB (Smith et al., 1981). These facts suggest that the choroid plexus is an important 
secretory organ. Similar to the endothelial cells of the BBB, the choroid plexus has a high 
capacity for drug metabolism and ATP production for energy dependent activities 
(Strazielle and Ghersi-Egea, 2000). 
 
In addition to secreting CSF, the CP is also a barrier. The tight junctions joining 
the epithelial cells greatly diminish the paracellular diffusion across choroid plexus 
(Zheng et al., 2003). Likewise various types of carriers and transporters regulate the 
penetration of solutes, nutrients and xenobiotics. Multiple carriers from SLC21 (OATP) 
and SLC22 (OAT/OCT) families are expressed in the CP. For examples, in rodents Oat3 
is located at the basolateral side of the CP epithelial cell of the BCB (Nagata et al., 2002), 
while Oatp3 and Oct2 are located at the apical side (Gao et al., 1999). In rodents, Oatp2 
has been found at both sides (Ito et al., 2005c). ABC transporters are also expressed at the 
BCB. In both human and rodents MRP1 and MRP4 are expressed at the basolateral side 
of the BCB (Nies et al., 2004; Leggas et al., 2004a) and P-gp and Bcrp are expressed at 
the apical side (Zhuang et al., 2006). Depending on the subcellular localization (either 
apical or basolateral), these ABC transporters might have a different impact on CSF 
penetration of their substrates. 
 
 
1.4 The effect of ABC transporters on camptothecin analogs CNS penetration 
 
Many factors affect CNS drug penetration, including the drug physiochemical 
properties, cerebral blood flow, enzymatic metabolism barrier (Johnson and Anderson, 
1996; Ghersi-Egea et al., 1988), and expression of influx or efflux transporters (Loscher 
and Potschka, 2005b). Camptothecin analogs are highly lipophilic drugs with a calculated 
octanol/water partition coefficient (cLogP) of 407 for topotecan lactone and 585 for  
irinotecan lactone (ChemDraw 9.0.1, CambridgeSoft Corporation, Cambridge, MA). The 
brain is a well perfused organ and topotecan is not a heavily metabolized drug. Thus, the 
topotecan CNS penetration is most likely controlled by active processes, either influx or 
efflux transporter system (e.g. ABC transporters). 
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Figure 1-3  Blood cerebrospinal fluid barrier. 
 
Cross-section of the blood-CSF barrier (BCB) at the choroid plexus. Choroidal epithelia 
with tight junctions (TJ) forms a dynamic interface between two circulating fluids, the 
choroidal blood and ventricular CSF.  The capillaries of the plexus are fenestrated.  
Abundant microvilli at the apical side of the choroidal epithelia and the basolateral 
infoldings greatly expand the surface area for molecular exchange at the BCB.  ABC 
transporters such as MRP1 and MRP4 are localized at the basolateral side of the 
choroidal epithelia, whereas MDR1 (P-gp) is present at the apical side of choroidal 
epithelia.  
 
Source: Modified with permission. Johanson CE, Duncan JA, Stopa EG, Baird A, 2005. 
Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF 
route. Pharm. Res. 22: 1011-1037. 
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1.4.1     The role of ABC transporters in vitro studies 
 
Numerous in vitro studies have demonstrated camptothecin analogs are substrates 
for several ABC transporters. P-gp has been shown to confer resistance to various anti-
cancer drugs including camptothecin analogs (Gottesman et al., 2002). Chen and 
colleagues first presented evidence that topotecan mediated cytotoxicity was reduced in a 
P-gp over-expressing cell line KB V1, and P-gp inhibitor verapamil restored the 
topotecan sensitivity (Chen et al., 1991). Hendricks et al. measured the topotecan IC50 
values in a colchicine-resistant cell line CHR5 (a typical P-gp overexpressing line). 
Examination of the IC50 values observed in colony-forming assays revealed that the 
CHRC5 cells were 15-fold more resistant to topotecan after a 1-h exposure compared 
with parental line (Hendricks et al., 1992b). Chu and colleagues demonstrated that the P-
gp overexpessing cell line KB-C2 was 6.3-fold more resistant to irinotecan than the 
parental cells (Chu et al., 1999b).  
 
BCRP was also well documented to be heavily involved in transport of several 
camptothecin analogs. Yang et al. first reported mitoxantrone-resistant human breast 
carcinoma cell line, MCF7/MX was cross-resistant to camptothecin analogues including 
topotecan (180-fold), 9-aminocamptothecin (120-fold), irinotecan (56-fold), and SN-38 
(101-fold) (Yang et al., 1995). Later it was demonstrated in mouse fibroblast cell lines 
that lack functional MDR1 and MRP1 genes, resistance to topotecan was mediated 
through BCRP gene amplification and overexpression (Brangi et al., 1999; Allen et al., 
1999). Maliepaard and colleagues reported topotecan directly induced BCRP 
overexpression in an ovarian tumor cell line (Maliepaard et al., 1999a). Efforts were 
made to circumvent the BCRP mediated resistance by using non-specific inhibitor 
GF120918 (Maliepaard et al., 2001c). In addition to the tumor cells, BCRP was also 
reported to be expressed in various normal tissues of multiple species, which suggests 
BCRP plays an important role in camptothecin disposition (Maliepaard et al., 2001a; 
Cooray et al., 2002; Eisenblatter et al., 2003; Cisternino et al., 2004). 
 
MRP4 is another ABC transporter reported to confer resistance to camptothecin 
analogs. Norris et al. reported intracellular SN-38 concentrations were reduced at least 4-
fold in MRP4 overexpressing HEK/293 cells. Functionally the MRP4 transfectants are 5-
times more resistant to irinotecan (Norris et al., 2005). Tian and colleagues performed a 
series of studies to compare the resistance to various camptothecin analogs conferred by 
MRP4. Based on the results from the MTT assay, with 48 h exposure time of the test 
drug, MRP4 conferred resistance to CPTs tested in the order 10-OH-CPT (14.21) > SN-
38 carboxylate (9.70) > rubitecan (9.06) > SN-38 lactone (8.91) > CPT lactone (7.33) > 
CPT-11 lactone (5.64) > CPT carboxylate (4.30) > CPT-11 carboxylate (2.68) (Tian et al., 
2005). They further demonstrated in a separate study that MRP4 conferred a 12-fold 
resistance to topotecan in the 4-hour drug-exposure MTT assay (Tian et al., 2006). 
Another MRP family member, MRP2, was also shown to have low affinity to irinotecan 
at high concentrations (e.g., 250 µM) (Chu et al., 1999a) . 
 
In summary, results of in vitro studies have identified that at least three ABC 
transporters including P-gp, BCRP, and MRP4 confer resistance to camptothecin analogs. 
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Based on the results of cytotoxicity assays, BCRP is an efficient transporter for topotecan 
whereas P-gp and MRP4 also transport topotecan but with much less efficiency. However, 
these in vitro results need to be confirmed in vivo before any therapeutic effort on 
modulating these transporters can be done.  
 
 
1.4.2    The utilization of targeted mutation mouse models of ABC transporters 
 
As in vitro results (e.g. drug accumulation assay or cytotoxicity assay) are not 
always translated in vivo, it is important to verify the exact role of these ABC 
transporters in drug disposition in vivo. The targeted mutation (knockout) mouse models 
provide unique tools to address these issues. Several knockout mouse models for various 
ABC transporters have been generated by different labs including Mdr1a(-/-), Mdr1a/b(-/-), 
Bcrp1(-/-). With further breeding of these mice, multiple transporters knockout mouse 
models can be generated such as Bcrp1/Mdr1a/b(-/-) (Jonker et al., 2005). The role of P-gp 
in vivo for vinblastine CNS penetration has been clearly defined by using Mdr1a(-/-) 
model (Schinkel et al., 1994). de lange et al. reported a typical P-gp substrate, rhodamine-
123, brain concentration was 4-fold higher in Mdr1a(-/-) mice than wild type (de Lange et 
al., 1998). The brain-to-plasma concentration ratio of an investigational drug CP-615003 
in Mdr1a/b(-/-) was 7-times that in wild type (Venkatakrishnan et al., 2007). These studies 
strongly suggest P-gp plays critical role in drug CNS disposition. 
 
Other in vivo studies utilizing knockout models do not seem to support in vitro 
results. For example, although in vitro irinotecan and SN-38 were substrates for MRP4, 
which also functionally conferred resistance in cell lines, they showed unchanged 
pharmacokinetics in Mrp4(-/-) mice (unpublished data). Most recently de Vries and 
colleagues reported the topotecan concentrations from whole brain homogenate in Mrp4(-
/-) were not substantially different from those in wild type mice(de Vries et al., 2007). 
These results could be explained by the overlapping substrate specificity of the 
transporters or, in other words, functional redundancy. It strongly indicates that if a drug 
is a substrate for a transporter in vitro, it does not necessarily translate to a significant 
role in vivo. The fact that a drug is usually a substrate for multiple transporters, makes it 
more difficult to distinguish the role of a single transporter on drug disposition and 
penetration into local tissues (e.g., central nervous system). These results warrant further 
investigation of the role of the ABC transporters in the CNS penetration of camptothecin 
analogs. The in vivo role of ABC transporters in camptothecin CNS penetration can be 
determined by comparing CNS drug penetration in the transporter deficient models with 
that in wild type mice. 
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1.5 Methods to evaluate CNS drug penetration 
 
 
1.5.1    Homogenization and autoradiography method 
 
Several methods can be used to determine the drug concentration and distribution 
in brain. The most common method is to directly collect the brain and extract total drug 
from the brain homogenate. This is the method that was used in the early drug 
distribution studies (Slordal et al., 1988; Nierenberg et al., 1991; Jain, 1989) and is still 
routinely used (Straathof et al., 1999; de Vries et al., 2007; Dickson et al., 2007). 
However, the homogenization method does not provide information that is crucial to 
understand the mechanism of CNS drug penetration. This approach mixes drug from 
three pharmacologically distinct compartments of the brain including capillary vessels, 
extracellular fluid (ECF), and intracellular fluid of brain parenchymal tissue.  With this 
method, the drug that is not bound to protein cannot be separately determined from the 
protein bound drug. This determination is critical as only the unbound faction of a drug is 
pharmacologically active and available for transport. Autoradiography is able to offer 
information on drug spatial distribution, but it does not discriminate parent drugs from 
the metabolites and just like homogenization it does not separate the unbound drug from 
the protein bound (Shapiro et al., 1988). To understand the mechanism of drug transport 
in the brain, it is crucial to sample unbound drug in specific compartments of the brain 
(e.g., ECF, vCSF). Currently, microdialysis is the only technique that is capable of this.  
 
 
1.5.2    Microdialysis 
 
Microdialysis was originally developed to monitor neurotransmitters in the living 
brain (Bito et al., 1966; Ungerstedt and Pycock, 1974). Very quickly this sampling 
technique found applications in drug delivery studies (Elmquist and Sawchuk, 2000). For 
the determination of CNS drug penetration, this technique has many advantages over the 
common method such as whole tissue homogenization. Advantages include continuous 
sampling without fluid loss, measurement of discrete anatomic compartments, clean 
samples suited for direct bioanalysis without prior processing, and measurement of 
unbound or pharmacologically active moieties (Benveniste and Huttemeier, 1990). 
However, microdialysis sampling does have disadvantages, including the fact that it is an 
invasive technique. The potential damage from probe implantation has been an issue 
debated in the microdialysis literature for many years.  In the 1980s, a series of studies 
were performed to address this concern. Particularly, Benveniste and colleagues designed 
a study to evaluate the effect of probe implantation on tissue damage at the blood brain 
barrier (Benveniste et al., 1987). They demonstrated in rats that the local cerebral blood 
flow and glucose uptake returned to normal levels as early as 24 hours after implantation 
of a microdialysis probe.  These results suggested the tissue damage could be managed if 
animals were given enough time to recover. Other disadvantages include that probes have 
to be calibrated in vivo and more sensitive analysis methods are usually required due to 
the small sample volume. Although microdialysis sampling does have these potential 
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concerns, the ability to directly address research questions related to CNS drug 
penetration makes this methodology particularly appealing.  
 
1.5.2.1 Probe material and perfusion fluid 
 
The functional part of a probe, the membrane, can be made of different materials 
including cellulose, copolymers, and polysulfone (Levine and Powell, 1989). These 
materials offer different molecular weight cut-off and permeability to solutes (Hernandez 
et al., 1986). It is also important that the membrane does not interact with the drug as this 
may affect dialysis result. The probes could be home-made or purchased commercially. 
Two major vendors provide microdialysis probes, and they are available in many 
different sizes (CMA microdialysis AB, Stockholm, Sweden; Bioanalytical systems, 
West Lafayette, IN, USA). 
 
In addition to the probe material, the perfusion fluid is also critical to the 
microdialysis results. In principle, the composition and pH of the perfusion fluid should 
be as close as to the fluid of the tissue in study. For example, artificial cerebrospinal fluid 
(aCSF) is usually used for microdialysis in CNS as it mimics the composition and pH of 
CSF (NaCl 148mM, KCl 4mM, MgCl2 0.8mM, CaCl2 1.4mM, Na2HPO4 1.2mM, 
NaH2PO4 0.3mM and Dextrose 5mM, pH adjusted to 7.4) (Leggas et al., 2004c).  
 
1.5.2.2 Probe recovery 
 
Determination of probe recovery is critical for success of microdialysis. As the 
perfusion fluid continuously flows through the probe, the concentration equilibrium will 
never be achieved. Only a fraction of the drug concentration in the tissue is extracted in 
the probe. This faction is defined as the probe recovery, and many factors affect this 
recovery. 
 
First, the length and diameter of probes (the functional part) significantly affect 
the probe recovery. The shorter or smaller probes give lower recovery simply because the 
perfusion fluid is allowed less time to exchange molecules with tissue fluid. For studies 
in mice, the probes are usually constructed in a very small size. For example, the probes 
used in this work are only 1mm in length and 0.22mm in diameter (MD-2211 
Bioanalytical systems). Second, the perfusion flow rate also affects the recovery. The 
higher the flow rate the lower the recovery. In order to obtain enough recovery for 
microdialysis studies in CNS the flow rate can go as low as 0.5ul/min. Third, in vivo 
microenvironment influences the probe recovery significantly. Because the external 
media could differ considerably from tissue microenvironment, calibration in vitro does 
not predict the probe performance in vivo. For CNS studies, the probe recoveries could 
have significant variations in different experiments (de Lange et al., 2000).  
 
Several methods are available to calibrate probe recovery in vivo (de Lange et al., 
1997; de Lange et al., 2000). For example, no-net flux is time consuming, which is not  
realistic in our study. Internal standard real time method requires extra analysis approach. 
We will only discuss the method used in this work, the retrodialysis method. The idea 
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was first described by Stahle and Wang (Stahle, 1994; Wang et al., 1993). If a drug 
solution with known concentration is perfused through the probe in vivo at the same flow 
rate as in the experiment, a fraction of drug will then be delivered to the tissue. It was 
demonstrated that this delivered fraction was equal to the extracted fraction when the 
drug was in the tissue (Stahle, 1994; Wang et al., 1993). The drug concentrations in the 
perfusion solution (Cin) and in the solution exiting the probe (Cout) can be measured 
before or after experiment.  The recovery of the probe can then be calculated as 
 
in
outin
C
CCR −= . 
 
 
1.5.3    Pharmacokinetic considerations 
 
Based on the assumption that only the protein unbound drug is available for 
transport, a simple model (Figure 1-4) can be constructed to describe the drug transport 
between plasma and brain (Hammarlund-Udenaes et al., 1997; Wong et al., 1993). 
 
The free drug concentration in plasma and brain ECF or ventricular CSF can be 
described by the following set of differential equations: 
 
brainuoutplasmauin
plasma
plasma CCLCCLCLRdt
dC
V ,,inf **)(* ++−=  (Eq. 1-1) 
 
brainuoutplasmauin
brain
brain CCLCCLdt
dCV ,, *** −=  (Eq. 1-2) 
 
where Vplasma  is the volume of distribution of the free drug in the plasma compartment 
(L/m2), Vbrain is the apparent volume of distribution of the free drug in the brain (L/m2), 
CL is the total clearance of the drug from plasma (L/h/m2), CLin and CLout are 
intercompartmental clearance between plasma and brain (L/h/m2), Rinf is the constant  
infusion rate (μg/h/m2). Integrating equation (1-2) from time zero to infinity and 
rearranging, we can obtain (Cbrain = 0 at time zero and infinity): 
 
∞−
∞−
= 0
0
plasma
brain
out
in
AUC
AUC
CL
CL
 (Eq. 1-3)  
 
where  is the area under the concentration-time curve of brain ECF or v
CSF drug integrated from time zero to infinity, ∞−0plasmaAUC  is the area under the 
concentration-time curve of plasma unbound drug integrated from time zero to infin
 
∞−0
brainAUC entricular 
ity. 
 
 18
Plasma Brain (ECF/CSF)
Vbrain, Cu, ECF/CSFVplasma, Cu, plasma
BBB/BCB
CLin
CLout
Rinf/
i.v.bolus
CL
 
 
 
Figure 1-4  General two-compartment model for drug transport between plasma 
and brain. 
 
Vplasma  is the volume of distribution of the free drug in the body (L/m2), Vbrain is the 
apparent volume of distribution of the free drug in the brain (L/m2), Cu, plasma is the protein 
unbound drug concentration in the plasma (μg/ml), Cu, ECF/CSF is the protein unbound drug 
concentration in the brain (ECF or CSF) (μg/ml). CL is the total clearance of the drug 
from plasma (L/h/m2), CLin and CLout are intercompartmental clearance between plasma 
and brain (L/h/m2), Rinf is the constant infusion rate (μg/h/m2).  
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The clearance ratio CLin/CLout can serve as a general indicator for drug transport 
activities across BBB or BCB. Despite requirement of advanced pharmacokinetic 
modeling, this ratio could be obtained through compartmental analysis. Equation (1-3) 
converts the clearance ratio to the AUC ratio, which can be easily obtained through non-
compartmental analysis. This ratio has several interesting properties (Deguchi, 2002). 
 
When
∞−
∞−
0
0
plasma
brain
AUC
AUC  <1, active efflux transport from brain to blood is the most likely 
explanation (Hammarlund-Udenaes et al., 1997; Wong et al., 1993). However care must 
be taken because this AUC ratio reflects the overall drug clearance across the BBB or 
BCB. If the drug is heavily metabolized or eliminated through bulk CSF route the ratio 
will also be significantly lower than unity. Many drugs fall into this category including 
alovudine, morphine, colchicine and topotecan etc. (Stahle and Borg, 2000; Xie et al., 
1999; Desrayaud et al., 1997; Zhuang et al., 2006). 
 
When
∞−
∞−
0
0
plasma
brain
AUC
AUC
=1, passive diffusion (including non-energy dependent 
facilitated transport) is the most likely explanation. Drugs like codeine and cocaine are 
the typical examples in this category (Xie and Hammarlund-Udenaes, 1998; Hedaya and 
Pan, 1997). 
 
When
∞−
∞−
0
0
plasma
brain
AUC
AUC
>1, active influx transport from blood to brain is the most likely 
explanation. Although very few drugs has been shown to have such a property, the brain 
to plasma AUC ratio of unbound oxycodone was estimated to 3.0, which strongly 
suggested this drug had an active influx transport mechanism (Bostrom et al., 2006). 
 
By calculating this AUC ratio it is possible to quantify the drug transport 
mechanisms across the BBB or the BCB. One thing worth mentioning is that the AUC 
ratio is based on the assumption that only unbound drug is available for transport. Thus 
the total drug concentrations measured in plasma must be corrected with a protein 
unbound fraction (fu) to obtain the unbound drug concentrations before further analysis. 
 
 
1.5.4    Modulation of ABC transporters by 4-anilinoquinazolines 
 
The 4-anilinoquinazolines (4-AQ) were originally developed as compounds to 
inhibit receptor tyrosine kinases (RTK) such as epidermal growth factor receptor 
(EGFR/Erbb1) and Bcr-Abl etc. (Wakeling et al., 1996). The mechanism of such 
inhibition was demonstrated to be mediated through competing for ATP binding site of 
the receptors (Denny et al., 1996). Currently there are several 4-anilinoquinazolines 
approved by FDA, including gefitinib (Iressa™, ZD1839), erlotinib (Tarceva™, OSI-
774), lapatinib (Tykerb™, GW572016), imatinib (Gleevec™, STI-571), dasatinib 
(Sprycel™, BMS-354825) and vandetanib  (ZactimaTM, ZD6474). 
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Stewart and colleagues first observed gefitinib showed minimal activity against a 
panel of 10 pediatric tumor xenografts that do not express the ERBB1 receptor. However, 
combined with irinotecan, significantly greater than additive activity was observed in 
four of eight tumor models that expressed BCRP. The hypothesis that gefitinib inhibited 
BCRP was supported by an in vitro study in which gefitinib potently reverse resistance to 
SN-38 only in cell lines overexpressing functional BCRP (Stewart et al., 2004b). Similar 
results were also reported by another group. Yanase et al. demonstrated gefitinib reversed 
SN-38 resistance in BCRP-transduced human myelogenous leukemia K562 
(K562/BCRP) and BCRP-transduced murine lymphocytic leukemia P388 (P388/BCRP) 
cells (Yanase et al., 2004). 
 
Further studies have shown gefitinib not only strongly inhibited BCRP but also 
directly inhibited P-gp (Kitazaki et al., 2005; Nakamura et al., 2005; Yang et al., 2005). 
These results suggested a combination of gefitinib and camptothecin analogs could be 
clinically effective in ABC transporter overexpressing tumors. Leggas and colleagues 
demonstrated gefitinib modulated the function of Bcrp and Mdr1 in vivo by using 
targeted mutation mouse models. Gefitinib increased oral absorption and decreased 
systemic clearance of topotecan in both Bcrp(-/-) and Mdr1a/b(-/-) mice (Leggas et al., 
2006). 
 
Based on these results, gefitinib was used as an ABC transporter modulator in this 
work.  
 
 
1.6 Blood brain tumor barrier (BTB) 
 
Although brain tumors still present some features of normal BBB, the 
pathological conditions significantly alter the BBB properties (Baluk et al., 2005). To 
distinguish from normal BBB, the brain tumor BBB is referred to as blood brain tumor 
barrier (BTB). As we have discussed the properties of normal BBB, this section we will 
focus on the properties of BTB under pathological conditions.  
 
 
1.6.1    The factors affecting BTB 
 
1.6.1.1 Disrupted tight junctions 
 
As mentioned in section 1.3.1, cerebral capillary endothelial cells are joined by 
tight junctions, these structures are clearly disrupted in BTB. Tight junction assembly 
requires multiple proteins including occludin, claudins, ZO-1, catenin, E-cadherin and 
actin etc (Wolburg and Lippoldt, 2002). Some of the proteins are missing or down-
regulated in brain tumor vessels.  
 
Sawada et al. reported the ZO-1 protein expression was reduced in 26 human 
astrocytomas compared with normal brain tissue by using immunohistochemistry 
(Sawada et al., 2000). Leibner and colleagues screened the expression of several junction 
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proteins in human glioblastoma multiforme. Claudin-1 was lost in the majority of tumor 
vessels and claudin-5 and occludin were significantly down-regulated in hyperplastic 
vessels (Liebner et al., 2000). Papadopoulos et al. studied the occludin expression in 
astrocytomas in different grades. It was demonstrated the immunostaining was inversely 
correlated with the tumor grades (Papadopoulos et al., 2001). A transmission electron 
microscopy study directly showed the open tight junctions in microvessels of human 
astrocytomas (Arismendi-Morillo and Castellano, 2005). These studies suggest tumor 
vasculature is structurally deficient in molecules that are crucial to maintain the BBB 
integrity.  
 
1.6.1.2 Abnormal morphology of blood vessels 
 
In addition to the disregulated expression of tight junction proteins, the tumor 
blood vessels are usually torturous and irregular (Baluk et al., 2005). As shown in Figure 
1-5 a scanning electron micrograph, the luminal surface of normal blood vessel was 
smooth and covered by tight endothelial cells.  In contrast in a pancreatic islet tumor, the 
blood vessel was rough and irregular and the lumen was significantly smaller. In addition 
to endothelial cells, other components of blood vessels including pericytes or muscle 
cells and basement membrane are all abnormal (Baluk et al., 2005) in tumor. 
Consequently the irregular blood vessels tend to reduce the blood flow to the 
tumor(Carmeliet and Jain, 2000; Baluk et al., 2005; Hashizume et al., 2000). It is 
believed that the observed features of tumor blood vessel prevail in all solid tumors. 
 
1.6.1.3 Angiogenesis related events 
 
While blood vessel growth is usually quiescent in adults, the tumor growth 
requires neo-angiogenesis (Folkman, 1971). Vascular endothelial growth factor (VEGF) 
has been identified as the most potent and critical angiogenic factor (Ferrara, 2004). 
VEGF expression is kept on a low level in normal tissues but greatly increased in brain 
tumor tissues. Weindel and colleagues analyzed VEGF expression level in 26 brain tumor 
surgical specimens (Weindel et al., 1994). PCR analysis revealed the VEGF mRNA level 
in malignant gliomas was increased 20 to 50-fold compared with low-grade tumors. In 
addition, using a radioreceptor assay it was possible to detect high VEGF-like activity in 
the cyst fluids of brain tumors, indicating the accumulation of VEGF and other 
permeability factors in brain tumor cysts (Weindel et al., 1994). These results were 
corroborated by Strugar and colleagues who found VEGF expression was well correlated 
with peritumoral brain edema status, which suggested VEGF expression increased the 
blood vessel permeability (Strugar et al., 1995). In addition to direct expression of VEGF, 
other pro-angiogenic mechanisms were also activated. Nabors and colleagues have 
shown that HuR, an mRNA stabilizer, is consistently expressed in malignant brain tumors. 
HuR was further demonstrated to stabilize cytokines such as VEGF, Cyclooxygenase-2, 
IL-8 and TGF-β etc., which are known to be involved in angiogenesis (Nabors et al., 
2001).  
 
A consequence of active angiogenesis is the increased activity of basement 
membrane metabolism (Kalluri, 2003). Basement membrane, a specialized extra-cellular 
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Figure 1-5  Blood endothelial cells in normal or tumor tissues. 
 
A) Capillary endothelial cells in normal pancreatic tissue. B) Capillary endothelial cells 
in pancreatic cancer tissue  
 
Source: Reprinted with permission. Baluk P, Hashizume H, McDonald DM, 2005. 
Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15: 
102-111. 
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matrix, is a structural and functional component of the integrated BBB. About 50 proteins 
make up the basement membrane, 50% of which is composed of collagen (especially type 
IV) (Kalluri, 2003). Other components include nidogen, laminin, and perlecan. These 
proteins are highly crosslinked in an organized way to support the vascular endothelial 
cells. For angiogenesis to occur from the existing blood vessels the basement membrane 
has to be degraded first. The degradation process is also highly regulated with multiple 
enzymes involved such as matrix metalloproteinases (MMPs) and collagenases (Arroyo 
et al., 2007; Rundhaug, 2005). The basement membrane degradation generates many 
fragments from the structural components, which have either pro or anti-angiogenic 
effects (Kalluri, 2003; O'Reilly et al., 1994; Colorado et al., 2000; Kamphaus et al., 2000; 
O'Reilly et al., 1997; Maeshima et al., 2002; Hamano et al., 2003; Carmeliet and Jain, 
2000). With tumor growth, basement membrane is degraded and reconstructed through 
the process of tumor induced neo-angiogenesis. All these angiogenetic activities affect 
the permeability of blood vessel. Due to its complexity, the overall influence on drug 
penetration is unpredictable.  
 
1.6.1.4 Other molecular events 
 
In normal BBB, the vesicular transport activity is very low. However this low 
transport mechanism could be activated in BTB due to the disregulation of certain 
molecular events. Early studies by Black and colleagues have shown that bradykinin and 
leukotriene C4 (LTC4) increased molecular transport across the blood-tumor barrier 
(BTB) (Hashizume and Black, 2002). It was also demonstrated that this increased 
transport was not mediated through tight junction opening but rather through enhanced 
vesicular transport (Hashizume and Black, 2002). The authors further reported that the 
overexpressed calcium-dependent potassium (KCa) channels and the ATP-sensitive 
potassium (KATP) channel in tumor capillaries were responsible for the enhanced 
transport activity (Ningaraj et al., 2003; Ningaraj et al., 2002). These data suggest another 
approach is needed for specific drug delivery to brain tumors.  
 
 
1.6.2    Early studies on drug penetration in the brain tumors 
 
Reliable drug penetration data in brain tumors are very limited. Early studies 
mainly focused on the construction of various brain tumor models and measurement of 
blood vessel permeability by using autoradiography. These studies demonstrated the BTB 
was generally more permeable than the normal BBB (Groothuis et al., 1982; Hasegawa et 
al., 1983; Shapiro and Shapiro, 1986; Shapiro, 1985; Groothuis et al., 1984).  
 
The early studies on drug CNS penetration mainly focused on methotrexate. 
Slordal et al. reported a normal brain to plasma methotrexate concentration ratio of 0.2 in 
rats (Slordal et al., 1988). Nierenberg et al. reported greater methotrexate concentrations 
in and near brain tumor than in ventricular CSF or serum in human adults (Nierenberg et 
al., 1991). However the brain tissue homogenate analysis neither discriminated the drug 
in extracellular fluid from intracellular fluid, nor separated the free drug from the protein 
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bound drug. The true penetration of methotrexate into the brain/brain tumor could be 
overestimated. 
 
 
1.6.3    In vivo microdialysis studies on drug penetration through BTB 
 
A few studies using a microdialysis approach demonstrated methotrexate 
penetration into brain tumors were much lower than determined by homogenization 
method in rats. With an i.v. infusion of methotrexate at 75 mg/kg, de lange et al. reported 
that the brain tumor to plasma AUC ratio (AUCbrain/AUCplasma) was 0.12 compared with 
normal brain to plasma ratio 0.05 (de Lange et al., 1995). However in this study the brain 
tumor model was constructed from R-6 rhabdomyosarcoma instead of a brain tumor line 
and the microdialysis probe was calibrated in vitro, which left some uncertainty for the 
accuracy of the results.  
 
According to Groothuis an animal brain tumor model should meet two criteria: 1) 
the tumor should originally be a brain tumor and 2) the tumor proliferation and 
histological grading should be predictable and reproducible (Groothuis et al., 1983). With 
these criteria Devineni et al. constructed a rat glioma model (RG-2) to study methotrexate 
brain tumor penetration (Devineni et al., 1996a). Although AUCbrain/AUCplasma was 
similar (0.05) in tumor and normal brain, the absolute AUC value in tumor was much 
higher (584 µg·min/ml) than normal brain (172 µg·min/ml). However the drug clearance 
and distribution volume were significantly lower in tumor bearing rats than normal ones. 
The authors attributed it to the loss of fluid volume in tumor bearing animals. Further 
pharmacokinetic modeling analysis showed the mass transfer coefficient across the BTB 
was much greater (8.9 ×10-4 ml/min) than the BBB (2.75 ×10-4 ml/min). This study 
suggested the methotrexate had a higher penetration rate in brain tumor than normal brain 
tissue.  
 
Dukic et al. investigated methotrexate penetration in two different rat glioma 
models. CNS1 presented a proliferation rate twice as much as C6 did in vivo. As a result 
of which, the CNS1 had more active neo-angiogenesis activity than C6. After a fast i.v. 
infusion of methotrexate 50 mg/kg, brain drug concentrations were determined by 
cerebral microdialysis. The final AUCbrain/AUCplasma ratio in CNS1 model was lower than 
in C6 model. In addition, the in vivo recoveries in tumor tissue were significantly 
different between the two tumor models. These results suggested the drug penetration not 
only depended on the presence of the tumor but also on the tumor model itself (Dukic et 
al., 2004).   
 
Nakashima et al. determined the cisplatin distribution in a 9L rat glioma model. 
Cisplatin (3.5 mg/kg) was administered as a selective intracarotid infusion for 30 min. 
Blood samples were collected through femoral vein and cerebral microdialysis samples 
were collected every 10 min for 120 min. The cisplatin plasma protein unbound fraction 
was also estimated. With this setting the brain to plasma AUC ratio of unbound cisplatin 
was determined to be 0.69 in tumor tissue and 0.04 in normal brain (Nakashima et al., 
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1997). The study provides an example that CNS penetration of a hydrophilic drug (e.g. 
cisplatin) can be significantly increased in tumor tissue compared with normal brain. 
 
Most recently, Appraraju et al. reported a pyrimidine nucleoside analogue, 
gemcitabine, also had a higher penetration in a C6 rat glioma model. Following an i.v. 
bolus injection of gemcitabine (25 mg/kg), microdialysis samples were collected 15 min 
pose-dose and then every 30 min; blood samples were collected periodically over 8 hours. 
The brain to plasma AUC ratio was determined 0.19 in tumor tissue and 0.09 in normal 
brain (Apparaju et al., 2008). 
 
In summary, the in vivo microdialysis studies provided invaluable data, which 
indicated the BTB penetration for anticancer drugs varied significantly. The drug 
penetration depended on drug physiochemical properties, the tumor models, and the 
location of the tumor. Although these results suggested the drug penetration through the 
BTB was increased in comparison with that in the normal brain, they should not be 
extrapolated without caution.  
 
 
1.7 Summary 
 
The outcome for patients with malignant CNS tumors is currently very poor. 
Chemotherapy is an important treatment modality, however the exact role of 
chemotherapy for CNS tumor treatment is not clear. Where novel agents such as 
camptothecin analogs have demonstrated potent activity in preclinical studies, the results 
from clinical trials were quite disappointing. Although such a discrepancy could be 
attributed to inherent tumor insensitivity, it is also likely to be associated with inadequate 
drug delivery due to the presence of the BBB and the BCB.  
 
While the specialized structures of the BBB and the BCB protect the brain from 
either endogenous or xenobiotic toxins, they also limit the penetration of anti cancer 
drugs (e.g. camptothecin analogs). The fact that the ABC transporters are expressed at the 
BBB and the BCB provides an opportunity to modulate the permeability of the two 
membrane barrier systems. Although camptothecin analogs were substrates for multiple 
ABC transporters (e.g. P-gp, BCRP, and MRP4 etc.) in vitro, their in vivo role has not yet 
been confirmed. When microdialysis sampling technique is utilized in targeted mutation 
mouse models, the role of the ABC transporters in vivo can be better defined.  
 
 Pathological conditions significantly alter the BTB properties; as a result drug 
penetration through the BTB could differ from the normal BBB. It is of clinical interest to 
understand how camptothecin analogs penetrate through the BTB.  In vivo microdialysis 
technique is an invaluable tool to address this question. 
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1.8 Objectives 
 
 The major focus of this work was to define the in vivo role of two ABC 
transporters Bcrp and P-gp in determination of topotecan (a model drug of camptothecin 
analogs) penetration through BBB and BCB.  
 
However in order to accurately measure the drug concentration in CSF, the 
microdialysis probe has to be precisely implanted into mouse lateral ventricle. The 
conventional method doesn’t offer a reliable approach. Thus the first objective is to 
develop a reliable surgical procedure to implant a microdialysis probe into mouse lateral 
ventricle. 
 
The second objective was to determine the topotecan penetration in vCSF and 
ECF of brain parenchymal tissue by utilizing cerebral microdialysis in several knockout 
mouse models including Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b/Bcrp1(-/-). Pharmacokinetic 
models were developed to describe the data. 
 
With clear understanding of mechanisms of topotecan CNS penetration under 
normal physiological conditions in vivo we extended our investigation to topotecan 
penetration across BTB in an animal tumor models. The third objective is to determine 
the topotecan penetration in a human glioma (U-87) xenograft mouse model. 
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Chapter 2. A Modified Surgical Procedure for Microdialysis Probe Implantation 
in the Lateral Ventricle of an FVB Mouse∗ 
 
 
2.1 Introduction 
 
Microdialysis has been widely used to sample endogenous biochemicals (e.g., 
neurotransmitters) or drugs in many different tissues in situ.  It has many advantages over 
common extraction methods such as whole tissue homogenization.  These advantages 
include continuous sampling without fluid loss, measurement of discrete anatomic 
compartments, clean samples suited for direct bioanalysis without prior processing, and 
measurement of unbound or pharmacologically active moieties(Benveniste and 
Huttemeier, 1990). This technique has been well established in multiple studies 
evaluating the penetration of unbound drug in numerous tissues (Boschi and Scherrmann, 
2000; Bito et al., 1966; Meirieu et al., 1986; Lehmann, 1989; Arner et al., 1988; Ben-Nun 
et al., 1988). 
 
Microdialysis has been particularly useful for studying drug distribution in the 
central nervous system (CNS) including ventricular cerebrospinal fluid (CSF) and 
extracellular fluid (ECF) of brain parenchymal tissue. Our previous studies have 
demonstrated that the camptothecin analog, topotecan, has differential penetration into 
CSF and ECF of the FVB mouse model (Zhuang et al., 2006).  The results of our studies 
have shown that the brain ECF to plasma area under the concentration-time curve (AUC) 
ratio of unbound topotecan lactone was 0.2 compared with the ventricular CSF to plasma 
AUC ratio which was approximately 1.2 (Zhuang et al., 2006). These results emphasize 
the importance of having the ability to distinguish between separate anatomic 
compartments such as the penetration of a drug into the CSF versus the ECF.  
Microdialysis affords this unique advantage which when combined with sensitive and 
specific analytical methods provide an accurate and quantitative assessment of the CNS 
penetration of a drug. 
 
Although CNS drug penetration studies could be performed in larger animal 
models such as the rat, dog, or nonhuman primate, the murine models may be 
manipulated genetically in ways that are not possible in the larger models.  This provides 
an important tool to address mechanistic questions such as those related to drug transport 
by making use of transporter knock-out mouse models (Jonker et al., 2002; Jonker et al., 
2005; Schinkel et al., 1997) and transporter modulators (e.g., gefitinib).  Our first studies 
in the mouse model used previously published surgical procedures that were designed to 
primarily to assess drug penetration into brain ECF only.  We adapted those techniques to 
assess topotecan penetration in both ventricular CSF and brain ECF.  Although these 
techniques were successful, they were technically very challenging and required large 
numbers of animals to get the required data.  Moreover, we found slight anatomical 
differences between strains of mice.  Therefore, we needed a more robust, reliable, and 
                                                 
∗ Reprinted by permission. Shen J, Fraga C, Calabrese C, McCarville MB, Schaiquevich P, Stewart CF, 2008. A 
modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. J. Pharm. Sci. 
. 
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reproducible technique specifically for the FVB mouse model in order to enhance our 
studies of drug penetration through the BCB.  Thus, the objectives of the present study 
were to develop a surgical procedure to implant a microdialysis probe into the lateral 
ventricle of FVB mice, to verify probe position through imaging technology and review 
of histology, and finally to validate the procedure experimentally by assessing topotecan 
CSF penetration in the FVB mouse model alone and in the presence of a transporter 
modulator such as gefitinib. 
 
 
2.2 Materials and methods 
 
 
2.2.1    Drugs 
 
Topotecan (Hycamtin, GlaxoSmithKline, Philadelphia, PA) was prepared in 
sterile water at a concentration of 1 mg/ml. Gefitinib tablets (Iressa, AstraZeneca), 
containing 250 mg gefitinib per tablet, were pulverized. Gefitinib powder was wetted 
with 0.5% Tween 20 (20% v/v final volume) and suspended in carboxymethylcellulose 
(0.25% w/v) to a final concentration of 40 mg/mL. 
 
 
2.2.2    Animals 
 
FVB female mice (Taconic, Germantown, NY) weighing 20-25g were used for 
this study. The mice were maintained on a 12 hour light/dark cycle with free access to 
food and water. After surgery, the mice were housed individually in cages. All 
procedures were approved by St. Jude Institutional Animal Care and Use Committee and 
in accordance with the Association for Assessment and Accreditation of Laboratory 
Animal Care (AALAC). 
 
 
2.2.3    Stereotaxic coordinates calculation and adjustment 
 
To define the axes, X was described as medial/lateral (left+/right-) movements 
along a horizontal line perpendicular to the midline on the skull.  Y was set as anterior 
(+)/ posterior(-) movements along the line parallel to the midline of the brain.  Finally, Z 
was set as dorsal(+)/ventral(-) vertical movements into the brain.  Although this study 
was performed in FVB female mice (20-25g), our initial coordinates were based on the 
C57BL/J6 strain as it was the only mouse strain with published stereotaxic coordinates in 
the brain (Franklin, 1997). 
 
First, we selected a region that included coronal sections from bregma -0.1mm to 
bregma -0.58mm, and measured the Z coordinates of the roof and bottom of the right 
lateral ventricle. The coordinates were then plotted on a chart with dimensions Y and Z as 
shown in Figure 2-1A, where X is 1mm lateral to the midline. Second, a right triangle 
was constructed to represent the ventricle geometrically. Based on the triangle, a 
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marginal angle α could be calculated where the angle α=β=γ. Therefore, the 
tan(γ)=0.48/1.6=0.3, and γ=tan-1(0.3)=16.7 degree.  From these calculations, it was 
possible to theorize that at any angle greater than 16.7 degree, the probe should be in the 
lateral ventricle.  An angle of 20 degrees was chosen empirically to calculate the Y and Z 
coordinates on the skull surface for use during cranial surgery. The coordinates were 
calculated as Y=reference-1.3mm, Z=reference-2.1mm, as shown in Figure 2-1B 
(X=reference-1mm as mentioned above and angle α=20 degree). The reference was the 
corresponding coordinate of the bregma point. 
 
 
2.2.4    Cranial surgery 
 
The general surgical procedure has been previously described in detail (Leggas et 
al., 2004c). Briefly, the mouse was anesthetized with ketamine (Abbott Laboratories, 
Chicago IL)/xylazine (Butler Company, Columbus, OH). A guide cannula with an inner 
stylet (MD-2255, Bioanalytical Systems, West Lafayette, IN) was positioned in the 
lateral ventricle. Mice were allowed to recover for 3-5 days prior to insertion of the 
microdialysis probe (MD-2211, Bioanalytical Systems, West Lafayette, IN).  Animals 
were euthanized at the conclusion of each study.  The head was removed and immersed 
in 10% neutral buffered formalin (NBF) for fixation prior to histologic evaluation or 
micro-CT.  The stereotaxic coordinates were slightly adjusted and refined accordingly for 
subsequent studies based upon information gained from imaging techniques and 
histology. 
 
 
2.2.5    Ultrasound imaging 
 
Mice bearing the implanted microdialysis probe were anesthetized deeply with 
isoflurane 3-4% and maintained with a nose cone. Anesthesia was supplemented with 
intraperitoneal injections of ketamine/xylazine 0.2 mL/100 gm as needed.  The state of 
anesthesia was assessed periodically by “pinch” test of the rear paw for reflex response.  
The hair was shaved and the skin treated with betadine solution. A coronal incision was 
made and the skin retracted dorsally to expose the skull. The bone was etched and 
removed to create a “window” exposing the occipital region of the brain. The skin flap 
was pulled forward and re-attached along the original incision with surgical cement. 
Creation of this cranial “window” allows for direct imaging of the brain tissue with an 
ultrasound probe. 
 
A VisualSonics (Toronto, ON) Vevo 770 ultrasound machine and mouse imaging 
platform and monitoring system were used. After anesthesia, the mouse was placed in a 
prone position on the imaging platform with the chin extended. The 708 55MHz high- 
resolution, linear, transducer was secured in position over the skull vertex so that the  
lateral ventricles were visualized in the coronal plane (Figure 2-2A). We postulated that 
if the probe was properly positioned within the ventricular system, then injection of 
 
 
 
Figure 2-1  Schematic demonstration of stereotaxic coordinates calculation.   
 
A). Lateral ventricle coordinates of C57BL/J6 male mouse (coronal sections containing 
bregma -0.1 mm to bregma -0.58 mm) and right triangle model representing that part of 
the ventricle.     indicate the positions of the roofs and bottoms of ventricles in the coronal 
sections. See text for calculation steps. (B). Calculation for the coordinates on the skull 
surface that can be used in surgical procedure. 
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Figure 2-2  Ultrasound imaging study. 
 
A) Horizontal diagram of brain showing lateral ventricles (arrows) (B-E) Coronal 
ultrasound images of a mouse bearing an intracranial probe obtained B) Before the 
injection of sterile saline into the intracranial probe cannula. Note the slit-like appearance 
of the normal, non-expanded lateral ventricles (arrows). The cranio-caudal diameter of 
the left lateral ventricle is 0.13 mm.  C) This image obtained immediately after the 
injection of 100 µL of saline shows expansion of the lateral ventricles (arrows) to a 
cranio-caudal diameter of 0.21 mm. D) This image obtained 5 minutes after the first 
injection shows decompression of the lateral ventricles (arrows) to a cranio-caudal 
diameter of 0.08, suggesting circulation of the injected saline out of the lateral ventricles. 
E) This image obtained immediately after a second injection of 170 µL of sterile saline, 
shows a greater degree of ventricular expansion (arrows) relative to that seen in Fig 2-2C, 
to a cranio-caudal diameter of 0.29 mm. These findings were taken as evidence of proper 
probe position. 
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sterile saline into the probe cannula would expand the ventricles and this change would 
be readily apparent on ultrasound imaging. Therefore, we obtained continuous real-time 
and static ultrasound imaging before, during, and after an initial injection of 100 µL of 
sterile saline through the intracranial probe cannula followed 10 minutes later by a 
confirmatory, second injection of 170 µL of sterile saline. To document a change in 
ventricular size we measured the cranio-caudal diameter of the mid-portion of the left 
lateral ventricle on pre and post-injection images. 
 
 
2.2.6    Micro-CT analysis 
 
All micro-CT analyses were performed using an Explore LocusSP specimen 
scanner (GE Healthcare, Piscataway, NJ).  Briefly, mice were euthanized and the 
microdialysis probe was removed. MicroFil solution (Flow tech Inc., Carver, 
Massachusetts) was prepared in advance by mixing 2 parts of MV-diluent with one part 
MV compound. MicroFil solution (100-150 μl) was injected through the guide cannula 
with a 27 gauge needle syringe. Once the injection was complete, the microdialysis probe 
was immediately re-inserted into the brain through the guide cannula.  The MicroFil 
compound was allowed to solidify for 30 minutes at room temperature, and then the 
whole mouse head was removed and immersion fixed in 10% NBF for at least 24 hours. 
Before scanning skulls were suspended in 70% ethanol and immobilized using sponges. 
 
For intact skull imaging, specimens were analyzed at 80 kVp and 70 mA giving 
400 total views and an isotropic resolution of 28 µm.  After whole skull scanning and 
reconstruction, the cannula and probe were removed and the brain extracted.  The probe 
was then reintroduced into the brain and tissue immobilized as before in 70% ethanol.  In 
the case of excised brain imaging, a second scan protocol was designed that would allow 
soft tissue discrimination but retain the ability to resolve radio-opaque materials such as 
MicroFil.  This protocol included reduction in voltage to 55 kVp and increase in current 
to 118 mA.  In order to limit artifact noise during scanning, an average of 8 individual 
frames was used for each view.  By performing a 360° scan, 900 total views were 
obtained and an isotropic resolution of 16 µm achieved. 
 
 
2.2.7    Histology 
 
As mentioned previously, at the conclusion of a microdialysis experiment, the 
animal was euthanized and the brain removed and fixed in 10% NBF for at least 24 
hours.  The brain was then grossed by cutting into saggital segments, dehydrated, cleared 
and embedded in a paraffin block.  Sections were cut on a microtome at 4 µm thickness 
and every tenth section was collected and stained with haematoxylin and eosin.  All 
sections from a given block were examined microscopically to verify the location of the 
microdialysis probe via the track in the tissue (Zhuang et al., 2006). 
 
2.2.8    Microdialysis study in vCSF of FVB mice 
 
The details of the microdialysis procedure were previously reported (Zhuang et 
al., 2006; Hammarlund-Udenaes et al., 1997). Briefly on the day of an experiment, a 
microdialysis probe (MD-2211, Bioanalytical Systems, West Lafayette, IN) was flushed 
with artificial CSF (aCSF) and inserted through the cannula into the brain lateral ventricle 
of a FVB mouse. The aCSF perfusion rate was set as 0.5 μl/min. The probe was allowed 
to equilibrate in vivo for 1 hour. Topotecan was administered by i.v. bolus through the 
lateral tail vein at a dosage of 4mg/kg (Zhuang et al., 2006). Gefitinib was administered 
by oral gavage at a single dose of 200mg/kg one hour before intravenous topotecan. The 
dialysate samples were directly loaded onto a sample loop (2 μl) and analyzed through an 
online microbore HPLC system (Zhuang et al., 2006; Leggas et al., 2004c). During the 
microdialysis period, three plasma samples were collected from each mouse at 0.25, 1 
and 3 hours after topotecan administration.  The samples, which were processed and 
analyzed for topotecan lactone using a previously published HPLC assay with 
fluorescence detection, were then used to determine the topotecan disposition in that 
mouse as previously described (Zhuang et al., 2006). 
 
 
2.2.9    Microdialysis probe recovery 
 
At the completion of the microdialysis study, when the topotecan CSF 
concentration was undetectable, a two-hour washing period was allowed. Then the probe 
recovery was determined using an in vivo retrodialysis technique.  Previously in vitro 
recovery studies from our lab have shown that topotecan lactone and carboxylate have 
the same recovery (unpublished data); therefore, we used recovery of total topotecan to 
represent the recovery for each form of topotecan. A topotecan solution (50ng/ml) was 
prepared in artificial CSF and the total topotecan concentration (Cin) was determined by 
HPLC. The solution was perfused (0.5 μl/min) through the microdialysis probe and the 
first four measurements exiting the probe were averaged as Cout. The recovery (Rtopotecan) 
was estimated as shown in Equation 2-1: 
 
inoutintopotecan CCCR /)( −=  (Eq. 2-1) 
 
 
2.2.10    Noncompartmental analysis of vCSF pharmacokinetic data 
 
The pharmacokinetic analysis of topotecan lactone was performed for each mouse 
(Zhuang et al., 2006). Topotecan lactone concentrations in vCSF were corrected for the 
hydrolysis of topotecan lactone to the carboxylate that occurs in pH 7.4 artificial CSF as 
described previously (Leggas et al., 2004c). The AUC in vCSF from time 0 to infinity 
was estimated using the linear trapezoidal method with the addition of a residual area as 
depicted in Equation 2-2, 
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where Ci is the topotecan concentration in dialysate; Δt is the sample injection interval; 
Cn is the last measurable topotecan concentration; β is estimated by linear regression of 
the logarithm of the last 4-5 measurable concentrations. 
 
 
2.2.11    Compartmental analysis of plasma pharmacokinetic data 
 
Plasma topotecan lactone concentration-time data were first corrected for plasma 
protein binding using an unbound factor determined previously (i.e., 0.36) (Zhuang et al., 
2006). A two-compartment pharmacokinetic model was fitted to the plasma topotecan 
lactone concentration-time data using maximum a posteriori probability (MAP) Bayesian 
estimation as implemented in ADAPT II (D'Argenio and Schumitzky, 1979). 
Pharmacokinetic parameters determined included volume of distribution of central 
compartment (Vc), elimination rate constant (ke), and intercompartmental rate constants.  
Using these parameters, the unbound topotecan lactone concentrations in the plasma were 
simulated in ADAPT II. The area under the concentration-time curve from zero to 
infinity (AUC0→∞) for the unbound topotecan plasma was calculated by integration of the 
simulated concentration-time data from model estimates.  A ratio of the vCSF AUC to 
unbound plasma topotecan lactone AUC was calculated and used as a measurement of 
topotecan vCSF penetration (Hammarlund-Udenaes et al., 1997). 
 
 
2.2.12    Statistical analysis 
 
Statistical analysis was performed in Sigma Stat 3.1. The student’s t-test was used 
to compare the results of modified procedure with those of conventional approach. The 
difference was considered significant when p<0.05. 
 
 
2.3 Results 
 
 
2.3.1    Determination of stereotaxic coordinates 
 
We first used the calculated coordinates (X=reference-1mm, Y=reference-1.3mm, 
Z=reference-2.1mm, Angle α=20 degree) to implant cannulas/probes in the right lateral 
ventricle of FVB female mice (see Methods for details of calculation of coordinates). The 
postmortem histology showed the probe missed the ventricle on the Y axis by 0.5-0.7mm 
(Figure 2-3A); however, the X, Z, and angle α were acceptable.  We attributed this to 
differences in strains between FVB and C57BL/J6. We then adjusted the Y coordinate for 
subsequent studies. With an adjusted Y coordinate, the probe was determined to be 
precisely located in the lateral ventricle (Figure 2-3B). The final stereotaxic coordinates 
were determined as X=reference-1mm, Y=reference-0.8mm, Z=reference-2.1mm with an 
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Figure 2-3  H&E staining of saggital brain section after probe insertion.  
 
(A), microdialysis probe track (P) missing the lateral ventricle (LV) by using calculated 
coordinates. (B), microdialysis probe track within the lateral ventricle after coordinates 
adjusted. 
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angle α=20 degree leaning toward posterior. The reference is the corresponding 
coordinate of the bregma point. 
 
 
2.3.2    Ultrasound imaging study 
 
Due to the very small size of the probe, we were unable to confidently visualize 
the exact location relative to the lateral ventricles on the pre-injection ultrasound images 
(Figure 2-2B). However, during the first injection of saline, we observed an immediate 
expansion of the lateral ventricles that was readily apparent on ultrasound imaging and 
confirmed by an increase in the cranio-caudal diameter from 0.13 mm pre-injection 
(Figure 2-2B) to 0.21 mm post-injection (Figure 2-2C). Five minutes after the first 
injection, the lateral ventricles were smaller, measuring 0.08 mm in diameter, (Figure 2-
2D) suggesting circulation of the saline out of the lateral ventricles. During the second 
injection, the ventricles again immediately expanded, this time to a greater degree than 
after the initial, smaller volume, injection, to a diameter of 0.29 mm (Figure 2-2E). 
These imaging results were interpreted as evidence of proper placement of the probe into 
the lateral ventricle. 
 
 
2.3.3    Micro-CT imaging analysis 
 
In order to capture a direct image of the cannula/probe in the ventricle, a high 
resolution micro-CT analysis was performed.  To confirm placement of the probe in the 
lateral ventricle, radio-opaque polymer MicroFil was infused through the implanted 
cannula.   The location of the polymer, cannula, and probe was determined using micro-
CT. The tip of the probe was located in the lateral ventricle with the whole head scan in 
both coronal (Figure 2-4A) and saggital (Figure 2-4B) planes. By imaging the excised  
brain (Figures 2-4C and 2-4D), in the absence of artifacts introduced by the metal 
screws implanted to secure the cannula, produced a superior to demonstrate the relative 
position of the probe in the right lateral ventricle. 
 
 
2.3.4    Topotecan penetration through blood CSF barrier in FVB mice 
 
With the coordinates determined and probe placement verified through imaging 
techniques (ultrasound and micro-CT) and histologic review, this modified surgical 
procedure was applied to placement of microdialysis probes for the study of topotecan 
penetration into vCSF.  During a baseline period prior implementation of this modified 
technique, our previous technique for probe placement was utilized. Of 20 microdialysis 
studies conducted during this period results from seven studies were interpretable (based 
on histological verification) for a success rate of approximately 35%.  However, with 
implementation of the modified surgical procedure for microdialysis probe implantation, 
results from 14 of the next 20 studies were interpretable for a success rate of 70%. 
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Figure 2-4  MicroCT analysis of intact head and excised brain following MicroFil 
infusion.  
 
For the whole head scan (coronal plane (A) and saggital plane (B)) the coronal slice (A) 
is orientated in plane with the microdialysis probe to show the insertion path. The excised 
brain scan shows posterior (C) and lateral (D) views. LV = Lateral Ventricle; P = Probe. 
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A noncompartmental approach was used to directly calculate the unbound 
topotecan lactone AUC from the vCSF microdialysis data.  A two-compartment 
pharmacokinetic model was fitted to the unbound topotecan lactone plasma 
concentrations to estimate the pharmacokinetic parameters (Zhuang et al., 2006; 
D'Argenio and Schumitzky, 1979). Based upon these pharmacokinetic parameters, the 
plasma concentrations were then simulated using ADAPT II (D'Argenio and Schumitzky, 
1979)  and the plasma AUC was calculated using a log-linear trapezoidal approach. In 
contrast to previously published results, the unbound topotecan (TPT) lactone 
concentrations measured in vCSF were much higher with this modified surgical 
procedure. Interestingly, lower unbound TPT lactone concentrations in vCSF in several 
experiments were observed, which were comparable to what was previously reported.  
However, after completion of histologic examination and analysis of CT results for these 
specific experiments, it was noted that the probe was not completely located within the 
lateral ventricle. In experiments where the probe was confirmed in the lateral ventricle, 
the vCSF to plasma AUC ratio of unbound TPT lactone (AUCu,CSF/AUCu,plasma) was 
calculated as 2.3±0.11 (see Table 2-1), which was almost twice as high as previously 
determined (AUCu,CSF/AUCu,plasma ~1.2) with the conventional approach (Zhuang et al., 
2006). The in vivo probe recoveries in vCSF were estimated 8.07± 2.42%. 
 
The effect of gefitinib modulation on topotecan vCSF penetration was also 
investigated with this modified procedure.  The vCSF to plasma AUC ratio of unbound 
TPT lactone was then determined as 1.02±0.03 (see Table 1), which was comparable to 
previously reported data (AUCu,CSF/AUCu,plasma approximately 0.98) (Zhuang et al., 
2006). The in vivo probe recoveries were 6.7± 1.0%. 
 
 
2.4 Discussion 
 
In this study, we developed a modified surgical procedure to implant a 
microdialysis probe into the lateral ventricle of FVB mice.  Utilizing stereotaxic 
coordinates calculated from C57BL/J6 as our starting point, we have refined those 
coordinates and changed the angle of the probe placement. This improved surgical 
procedure takes advantage of the width of the posterior region of the lateral ventricle and 
gains more space on the Z-axis (Figure 2-1B).  This resulted in greatly increased 
accuracy and precision of microdialysis cannula/probe insertion into the ventricle.   To 
determine if these modifications would impact our results, several microdialysis studies 
of topotecan in ventricular CSF were performed.  The results of these studies showed that 
when the microdialysis probe was consistently placed in the lateral ventricular space the 
topotecan ventricular CSF to plasma AUC ratio was greater than that observed with the 
conventional technique.  
  
To gain insight into the CSF penetration of a compound, studies are often 
conducted in larger animal species (e.g., nonhuman primate (Blaney et al., 1993; Blaney 
et al., 1998; D'Argenio and Schumitzky, 1979)), primarily because CSF samples can be 
collected directly via ventricular shunts or reservoirs.  Although accurate placement of 
ventricular probes requires skill and technique, it can be done relatively easy compared  
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Table 2-1  vCSF to plasma AUC ratios of unbound topotecan lactone at the 
presence or absence of gefitinib. 
 
Treatment Animal ID AUC ratio 
#1 2.22 
#2 2.32 
#3 2.18 
#4 2.45 
#5 2.30 
#6 2.45 
Topotecan 4mg/kg 
Average 2.32±0.11* 
   
#7 1.05 
#8 1.01 
#9 0.99 
Topotecan 4mg/kg+gefitinib 
200mg/kg 
Average 1.02±0.03** 
* Mean±SD, n=6 
**Mean±SD, n=3 
P<0.05 (Student’s t test) 
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with smaller animal species. However, small animal models (e.g., mice) present a 
significant technical challenge because of the extremely small size of their ventricles and 
CSF volume (Cirrito et al., 2003).  
 
In order to investigate the drug penetration through the blood CSF barrier (BCB) 
utilizing microdialysis, it is crucial to insert the probe directly into the lateral ventricle. 
Upon examination of coronal sections in the anterior region of the mouse lateral 
ventricle, it is relatively deep (1mm) but narrow (~0.3mm), and the posterior portion is 
relatively wide (0.8-1mm) but shallow (0.5-0.8mm). The microdialysis probe itself is 
1mm in length and 0.22mm in diameter. Smaller probes are not practical as the recovery 
is usually low. Due to the dimensional limitations in the mouse, it is extremely difficult to 
precisely implant a probe into the ventricle using the conventional perpendicular insertion 
method.  Moreover, it requires extensive technical expertise and is labor intensive 
requiring many experiments to collect the appropriate data. Many times after histologic 
review, data from experiments are excluded when the probe is determined to have 
penetrated the ventricle or not deep enough.  Thus the objective of the present study was 
to develop and validate a modified method to implant a microdialysis probe at an angle 
and from a more dorsal insertion point into the lateral ventricle of a mouse.  
 
This modified procedure also has application for ventricular drug delivery in 
mouse models. Although, methods for intracerebral injection of drugs in mice were first 
described by Haley and McCormick (Haley and Mccormick, 1957) and modified by 
Clark (Clark et al., 1968) and Boschi (Boschi et al., 1981), due to similar reasons as 
discussed above, the procedures lack accuracy and reliability. If the conventional 
perpendicular targeting method is used, the width advantage (posterior part of the 
ventricle) is sacrificed for depth (anterior part of the ventricle). This modified procedure 
could help deliver drugs into the ventricle much more accurately. 
 
Although this study was initiated to develop a more reliable and robust surgical 
procedure, unexpectedly the observation that higher unbound topotecan lactone 
concentrations were present in the vCSF suggests the modified procedure positions the 
probe for superior performance than the conventional perpendicular method. 
Consequently the vCSF to plasma AUC ratio of unbound topotecan lactone was almost 
doubled (2.3±0.11) with the modified procedure over that previously reported (1.2±0.06) 
with the conventional perpendicular method. Interestingly when mice were pretreated 
with gefitinib the AUC ratios obtained with the modified procedure (1.02±0.03) were 
comparable to those obtained with the conventional method (0.98±0.05) (Zhuang et al., 
2006). Gefitinib has been reported to modulate ATP-binding cassette (ABC) transporters 
and inhibiting active transport of their substrates (e.g. topotecan, irinotecan) (Leggas et 
al., 2006; Stewart et al., 2004b). This laboratory previously reported the expression of 
two ABC transporters, breast cancer resistance protein (Bcrp1) and P-glycoprotein (P-gp) 
on the apical side of choroid plexus epithelial cells in FVB mice (Zhuang et al., 2006). 
Based on the results of this study the modified surgical procedure demonstrated enhanced 
positioning of the microdialysis probe that affords quantitation of active drug transport 
superior to the conventional perpendicular method. However when gefitinib is present, 
the active drug transport was inhibited. When this occurs only passive diffusion is 
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permitted, and as would be expected, both methods give similar values, 
(AUCu,CSF/AUCu,plasma around 1.08).  Therefore the underestimation of drug penetration in 
vCSF could be caused by either partial probe contact of vCSF (puncture through the 
ventricle) or non-optimal position of the probe in lateral ventricle (against the wall of the 
ventricle).  
 
Although it is not exactly clear why this modified procedure more accurately 
quantitates active CSF drug efflux, it is likely related to the choroid plexus distribution in 
the lateral ventricle and the direction of CSF circulation in the ventricular system. The 
choroid plexus is not evenly distributed through the whole lateral ventricle, but is dense 
in the posterior region. CSF is secreted by the choroid plexus located in lateral ventricles 
and “percolates” down to the third and fourth ventricle, and then eventually out of 
ventricular system (Johanson et al., 2005). This modified procedure orients the probe in 
the posterior part of lateral ventricle, which contains dense segments of choroid plexus 
and also is in the direct route of the CSF as it flows down to the third ventricle. In 
contrast, the conventional perpendicular method places the probe in the anterior region of 
the ventricle, which is not only narrow but also contains much less choroid plexus.  
Additionally, this positioning is not in the route of CSF flow, which is in a rostral/caudal 
direction.   
 
Due to possible strain differences, the calculated coordinates based on C57BL/J6 
mice may not be directly applied to other mouse strains.  This report demonstrated 
refinement of the coordinates for the FVB strain. The optimal coordinates for a specific 
mouse model should be experimentally optimized by either postmortem histologic 
inspection or by imaging technology. In this case, Y coordinate for FVB female mice was 
adjusted by 0.5-0.7mm. However the calculated coordinates are invaluable as an initial 
reference point. Finally we propose that this modified procedure may be used for 
microdialysis experiments investigating the presence of a compound (e.g., 
neurotransmitters) or drug penetration into the vCSF in mice. 
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Chapter 3. Penetration of Topotecan Lactone across Blood-Brain Barrier and 
Blood-CSF Barrier: Differential Role of P-Glycoprotein (P-gp) and Breast Cancer 
Resistance Protein (BCRP) 
 
 
3.1 Introduction 
 
Treatment of patients with primary central nervous system (CNS) tumors 
continues to challenge both physicians and researchers. The overall survival rate for these 
patients has not significantly improved over the last three decades (Jemal et al., 2007). 
Although surgical resection and radiotherapy are the cornerstones of therapy, 
chemotherapy is an important treatment modality for many patients. For example, in 
children less than three years old chemotherapy is preferred to avoid or delay the use of 
radiotherapy (Rutkowski et al., 2005). However, despite aggressive chemotherapy with 
currently available agents, clinical outcomes are far from satisfactory (Motl et al., 2006) 
and development of new chemotherapeutic agents is urgently demanded. 
 
One promising class of drugs, the camptothecin analogs (e.g., topotecan and 
irinotecan) have demonstrated potent antitumor activity when tested in a panel of human 
brain tumor xenograft mouse models (Houghton et al., 1995; Hare et al., 1997). However, 
disappointing results from clinical trials using these chemotherapeutic agents in patients 
with primary CNS tumors suggest that their in vivo brain penetration might be 
constrained by the presence of blood brain barrier (BBB) and blood cerebrospinal fluid 
(CSF) barrier (BCB) (Friedman et al., 1999b; Chamberlain, 2002; Cloughesy et al., 2002; 
Blaney et al., 1996; Stewart et al., 2004a; Bernier-Chastagner et al., 2005; Chintagumpala 
et al., 2006). The proteins of the ATP-binding cassette (ABC) transporter family are 
known to be expressed on the apical side of cerebral vascular endothelial cells, the major 
component of BBB (Cooray et al., 2002; Leggas et al., 2004a; Schinkel et al., 1994), and 
may play a significant role on the restriction of topotecan penetration into the brain, as 
recently shown (de Vries et al., 2007; Leggas et al., 2004a). In fact, camptothecins are 
substrates of multiple ABC transporters (Sparreboom et al., 2003; Gottesman et al., 2002; 
Loscher and Potschka, 2005a) and several in vitro studies have demonstrated that 
overexpression of human breast cancer resistance protein (Bcrp/ABCG2), P-glycoprotein 
(P-gp), or multidrug resistance protein 4 (MRP4) conferred resistance to topotecan (Yang 
et al., 1995; Maliepaard et al., 1999a; Tian et al., 2006; Hendricks et al., 1992b). 
 
We have reported that MRP4 (ABCC4) is expressed on the basolateral side of the 
choroid plexus epithelial cells in both humans and rodents (Leggas et al., 2004a). Taking 
advantage of an in vivo cerebral microdialysis technique that allows to measure unbound 
topotecan concentrations in selected tissues or anatomical compartments, we showed 
increased topotecan concentrations in CSF of Mrp4 knockout mice than wild type 
(Leggas et al., 2004a). This result suggests Mrp4 constrained topotecan penetration into 
CSF. However our further study in FVB wild type mouse demonstrated unbound 
topotecan lactone concentration in CSF was actually higher than that in plasma (Zhuang 
et al., 2006). The expression of Mrp4 cannot explain the observation. These data strongly 
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suggest that at least one other drug efflux pump exists to actively move topotecan from 
the blood into the CSF. 
 
We reported that murine Bcrp1 and P-gp were expressed on the apical side of the 
epithelial cells of choroid plexus (BCB) (Zhuang et al., 2006). As topotecan is also a 
substrate for Bcrp1 and P-gp (Yang et al., 1995; Hendricks et al., 1992b) it is highly 
probable that Bcrp1 and P-gp are together responsible for the high penetration of 
topotecan across the BCB. However in vivo data to support this hypothesis is lacking. 
 
Most recently Tellingen et al. reported P-gp and Bcrp1 working together in 
limiting the brain penetration of topotecan by using a brain homogenate method (de Vries 
et al., 2007). However the study did not distinguish the CSF compartment from the 
extracellular fluid (ECF) of brain parenchymal tissue. Furthermore the homogenate 
method may not explain the drug transport mechanisms across the BBB as it mixes the 
protein bound and unbound drug from brain microvessels, extracellular fluid, and 
intracellular fluid.  
 
A complete characterization of the differential function of BBB versus BCB in the 
topotecan brain pharmacokinetics could be of clinical relevance. For instance, it is 
reported that medulloblastoma patients have a better response rate as compared to glioma 
patients in several clinical trials with topotecan (Stewart et al., 2004a; Bernier-Chastagner 
et al., 2005; Chintagumpala et al., 2006). A reasonable hypothesis would be that 
medulloblastoma, due to its neuraxis location, has more access to CSF regulated by BCB. 
Glioma is more parenchymal tissue based with very limited CSF access and mainly 
perfused through cerebral capillary regulated by BBB. Localized pharmacokinetic 
sampling in the knockout mouse brain could clarify the mechanisms that control the 
topotecan penetration through the BBB and the BCB, and such knowledge could lead to 
an effective modulation strategy to enhance drug CNS penetration. However, sampling 
the mouse brain is challenging and requires special skills and equipments. 
 
To improve our understanding of the role of the ABC transporters in the in vivo 
CNS penetration of anticancer drugs, we aim at characterizing their differential function 
in the BBB and BCB barriers. Pursuing this goal, in the present study we take advantage 
of 1) knockout mouse models for Bcrp1 and P-gp, 2) the pharmacological effect of 
gefitinib as a modulator of the ABC transporters, and 3) a sampling technique 
(microdialysis) that allows the “online” characterization of the unbound concentrations of 
topotecan lactone and carboxylate in localized CNS compartments.  
 
 
3.2 Materials and methods 
 
 
3.2.1    Drugs and chemicals 
 
Topotecan hydrochloride (Hycamtin, GlaxoSmithKline, Philadelphia, PA) for use 
in pharmacokinetic studies was prepared in sterile water (1 mg/ml). Gefitinib tablets 
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(Iressa, AstraZeneca), containing 250 mg gefitinib per tablet, were pulverized. Gefitinib 
powder was reconstituted with 0.5% Tween 20 (20% v/v final volume) and suspended in 
carboxymethylcellulose (0.25% w/v) to a final concentration of 40 mg/mL. Topotecan 
solutions used for chromatography (1 mg/ml) were prepared in dimethyl sulfoxide 
(DMSO).  All other solvents and chemicals and solvents used were analytical grade or 
better. 
 
 
3.2.2    Animals 
 
FVB, Bcrp1(-/-) (Jonker et al., 2002), Mdr1a/b(-/-) (Schinkel et al., 1997), and 
Mdr1a/b(-/-)Bcrp1(-/-)  (Jonker et al., 2005) female mice weighing 20-25 g were ordered 
from Taconic, Germantown, NY. All targeted mutation mouse models are crossed on an 
FVB genetic background. The mice were maintained on a 12-hour light/dark cycle with 
free access to food and water. After surgery, the mice were housed individually in cages. 
All procedures were approved by St. Jude Institutional Animal Care and Use Committee 
and in accordance with the Association for Assessment and Accreditation of Laboratory 
Animal Care (AALAC). 
 
 
3.2.3    Topotecan plasma protein binding 
 
Topotecan lactone plasma protein binding was determined in plasma from each of 
the mouse models including FVB, Bcrp1(-/-), Mdr1a/b(-/-), and Mdr1a/b(-/-)Bcrp1(-/-). 
Topotecan lactone was added to plasma from each genotype to make a 500 ng/ml 
solution. Spiked plasma (0.5 mL) was added to a Centrifree YM-30 (Millipore 
Corporation, Billerica, MA) sample reservoir and centrifuged at 2000 g for 20 minutes. 
Topotecan was extracted from the protein and ultrafiltrate portion of the device, 
respectively, by adding 50 μL of sample immediately to 200 μL of cold methanol stored 
on dry ice. Samples were analyzed by an HPLC method as previously reported (Furman 
et al., 1996; Baker et al., 1996). Topotecan lactone fraction unbound was calculated as 
amount of unbound topotecan lactone divided by total amount of topotecan lactone in 
plasma. 
 
 
3.2.4    Brain surgery 
 
The procedure of brain surgery to implant a guide cannula for microdialysis study 
in vCSF (Shen et al., 2008) or ECF (Zhuang et al., 2006; Leggas et al., 2004c) has been 
previously reported. Prior to any surgery, the mouse was anesthetized with ketamine 
(Abbott Laboratories, Chicago IL) /xylazine (Butler Company, Columbus, OH).  Briefly, 
for the vCSF microdialysis study, the guide cannula (MD-2255, Bioanalytical Systems, 
West Lafayette, IN) was inserted into the lateral ventricle at an angle of 20 degrees 
posterior (1mm lateral, 0.8mm posterior, 2mm ventral to the bregma point). For the ECF 
study, the guide cannula was inserted vertically into the striatum (1.8mm lateral, 0.6mm 
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anterior, and 2mm ventral to the bregma point). After insertion of the cannula, a mouse 
was allowed three to five days to recover prior to any microdialysis experiment. 
 
 
3.2.5    Microdialysis in ventricular CSF and brain ECF 
 
The microdialysis procedure and probe calibration was previously reported in 
detail (Leggas et al., 2004c; Zhuang et al., 2006). Briefly, on the day of an experiment, a 
microdialysis probe (MD-2211, Bioanalytical Systems, West Lafayette, IN) was primed 
and flushed with blank artificial CSF (aCSF, NaCl 148mM, KCl 4mM, MgCl2 0.8mM, 
CaCl2 1.4mM, Na2HPO4 1.2mM, NaH2PO4 0.3mM and Dextrose 5mM, pH adjusted to 
7.4). The probe was inserted through the cannula into the brain lateral ventricle or 
striatum, and the aCSF perfusion rate was set at 0.5 μl/min. The probe was allowed to 
equilibrate in vivo for 1 hour. Topotecan (4 mg/kg) was administered by i.v. bolus 
through the lateral tail vein. The dialysate samples were directly loaded onto a sample 
loop (2 μl) and analyzed through an online microbore HPLC system (Leggas et al., 
2004c). Probe recovery was determined using the in vivo retrodialysis method after each 
experiment was completed. During the microdialysis period, three plasma samples were 
collected from a mouse at 0.25, 1, and 3 hours after topotecan administration for plasma 
pharmacokinetic analysis (Zhuang et al., 2006). At the completion of the microdialysis 
experiment, the mouse was euthanized, the brain was fixed in 10% neutral buffered 
formalin for 24 hours, and then embedded in paraffin.  To locate the microdialysis probe 
track, haematoxylin and eosin stained sections (4 µm) were examined microscopically. 
 
 
3.2.6    Microdialysis probe recovery 
 
Once the vCSF topotecan concentration was undetectable, a two-hour wash 
period was begun. At the end of the wash period, probe recovery was determined using 
the in vivo retrodialysis method with topotecan as calibrator. In vitro recovery studies 
done in our lab showed that topotecan lactone and carboxylate have the same recovery 
(unpublished data); therefore, we used recovery of total topotecan to represent the 
recovery for each form of topotecan. A topotecan solution (50 ng/ml) was prepared in 
artificial CSF and the total topotecan concentration (Cin) was determined by HPLC. The 
solution was perfused (0.5 μl/min) through the microdialysis probe and the first four 
measurements exiting the probe were averaged as Cout. The recovery (Rtopotecan) was 
estimated as shown in Equation 3-1: 
 
inoutintopotecan CCCR /)( −=  (Eq. 3-1) 
 
 
3.2.7    Noncompartmental analysis of brain topotecan data 
 
Pharmacokinetic analysis was performed for each mouse (Zhuang et al., 2006). 
Topotecan carboxylate and lactone concentrations in vCSF were corrected for the 
hydrolysis of topotecan lactone in pH 7.4 aCSF as described previously (Leggas et al., 
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2004c). The AUC of lactone and carboxylate in vCSF or ECF from time 0 to infinity was 
estimated using the linear trapezoidal method with the addition of a residual area as 
depicted in Equation 3-2: 
 
∑
=
−
∞→ +Δ+=
n
i
n
ii
brain Ct
CCAUC
1
10 *
2
β  (Eq. 3-2) 
 
where Ci is the topotecan concentration in the dialysate; Δt is the sample injection 
interval; Cn is the last measurable topotecan concentration; β is estimated by linear 
regression of the logarithm of the last 4-5 measurable concentrations.  
 
 
3.2.8    Topotecan plasma pharmacokinetics 
 
As with our previous murine microdialysis study (Zhuang et al., 2006), the goal of 
each plasma pharmacokinetic study was to assess the topotecan lactone systemic 
exposure. Because of logistical issues (e.g., blood volume), no more than three samples 
per mouse could be obtained, thus a limited sampling model was utilized to assess 
unbound topotecan lactone systemic exposure. Before this analysis could proceed, 
population mean and variances (i.e., population priors) for topotecan lactone 
pharmacokinetic parameter estimates were determined in each murine genotype model. A 
plasma pharmacokinetic study was performed for each genotype (Bcrp1(-/-), Mdr1a/b(-/-), 
and Mdr1a/b(-/-)Bcrp1(-/-)) and treatment (topotecan 4 mg/kg i.v. alone or topotecan 4 
mg/kg i.v. plus oral gefitinib 200 mg/kg) using the same approach previously described 
(Zhuang et al., 2006) to obtain the population mean and variance (estimated via 
NONMEM) for each pharmacokinetic parameter.  Briefly, for each of these studies six to 
seven mice were used and each mouse was randomly sampled four times out of five 
sampling time points (e.g., 0.25, 0.5, 1.5, 3 and 6 hours) by either retro-orbital or cardiac 
puncture at the final time point. Sample processing and topotecan lactone bioanalysis 
have been previously reported in detail (Baker et al., 1996; Furman et al., 1996; Zhuang 
et al., 2006). In the studies where the effect of gefitinib was evaluated, it was 
administered by oral gavage at a dosage of 200 mg/kg one hour before topotecan, which 
was administered through lateral tail vein injection (Zhuang et al., 2006).  
 
For each microdialysis experiment (e.g., topotecan with or without gefitinib pre-
treatment), a two-compartment pharmacokinetic model was fitted to the plasma topotecan 
lactone concentration-time data using maximum a posteriori probability (MAP) Bayesian 
estimation as implemented in ADAPT II (D'Argenio and Schumitzky, 1979). The 
population priors used for this MAP Bayesian analysis were determined for each 
genotype as described above.  The pharmacokinetic parameters estimated included 
volume of central compartment (Vc), systemic clearance (CLt), volume of peripheral 
compartment (Vp), and intercompartmental clearance (CLp). Using these parameters, the 
unbound topotecan lactone concentrations in the plasma were simulated for each 
experiment using ADAPT II. The area under the plasma concentration-time curve from 
zero to infinity ( AUC0→∞) for the unbound topotecan lactone was calculated by 
integration of the simulated concentration-time data from the model estimates.  
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The extent of CNS penetration of topotecan lactone was determined by the ratio 
of unbound topotecan lactone AUC in brain ECF or ventricular CSF to the unbound 
plasma topotecan lactone AUC (Hammarlund-Udenaes et al., 1997). Student’s t-test was 
used to compare the unbound topotecan lactone brain to plasma AUC ratio after each 
treatment. 
 
 
3.2.9    Three-compartment analysis of combined plasma and brain lactone 
pharmacokinetic data 
 
The previous assessment of topotecan CNS penetration was a hybrid of 
noncompartmental and compartmental determinations, so a three compartment model 
(Hammarlund-Udenaes et al., 1997; Gupta et al., 2006; Zhuang et al., 2006) was 
developed to fit unbound topotecan lactone concentration-time data in brain parenchymal 
ECF or vCSF and plasma as implemented in ADAPT II. The parameters describing 
topotecan disposition between the plasma and CSF or ECF (CLin, CLout and VECF or 
VCSF) were estimated for each individual mouse.  The estimation was performed by 
fitting the model to the CSF or ECF data with the plasma pharmacokinetic parameters 
(Vc, CLt, Vp , and CLp) fixed at the values obtained in the above described plasma 
pharmacokinetics section. To compare the noncompartmental and compartmental 
methods in estimation of AUC in the brain, we calculated the ratio of CLin to CLout 
obtained from the three-compartment analysis. Based on the relationship 
CLin/CLout=AUCbrain/AUCplasma (Wong et al., 1993), brain to plasma AUC ratios 
calculated from the noncompartmental and compartmental analyses were compared. 
 
 
3.2.10    Three-compartment analysis of plasma topotecan lactone and     
  carboxylate data 
 
To calculate the plasma carboxylate AUC (where data were available), models 
were developed to fit plasma lactone and carboxylate data simultaneously. A three 
compartment model was best fitted to our dataset (two compartments for lactone and one 
compartment for carboxylate). The goodness of fit was based on comparing objective 
functions and diagnostic scatterplots. Prior to pharmacokinetic analysis for an individual 
mouse, a population analysis was conducted in NONMEM VI (subroutine ADVAN6) to 
obtain the population means and variations of the model parameters. The individual 
mouse pharmacokinetic parameters were then determined in ADAPT II by using 
maximum a posteriori probability (MAP) Bayesian estimation. The carboxylate AUC 
was simulated with the estimated parameters in ADAPT II. The plasma carboxylate AUC 
was used to calculate plasma lactone to carboxylate ratio of unbound topotecan. 
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3.2.11    Immunohistochemistry 
 
Brains were collected from FVB, Bcrp1(-/-), and Mdr1a/b(-/-) mice (Taconic, 
Germantown, NY), fixed in 10% neutral buffered formalin overnight, and embedded in 
paraffin before sectioning. Using immunohistochemistry procedures previously reported, 
the presence of Bcrp1 and P-gp was assessed in these tissues (Zhuang et al., 2006).  The 
monoclonal antibody rat BXP-53 (1 µg/mL; Alexis Biochemicals, San Diego, CA) was 
used to detect Bcrp1 with rat IgG2a isotype as the negative control. The polyclonal rabbit 
anti-MDR antibody (2 µg/mL; C-19, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) 
and non-immunized rabbit IgG were used for P-gp detection in mouse brain and the 
negative control, respectively. Paraffin sections (3-5 µm) were stained using standard 
avidin-biotin complex immunohistochemical techniques. This consisted of streptavidin-
horseradish peroxidase combined with an antigen retrieval step (DAKO Corp., 
Carpinteria, CA), and the addition of an avidin-biotin (Vector Labs, Burlingame, CA) 
blocking step before primary antibody application. Primary antibodies were incubated 
overnight at 4ºC followed by secondary antibody (4 µg/ml), either biotinylated anti-rat or 
anti-rabbit. Results were visualized with diaminobenzidine (DAKO), counterstained with 
haematoxylin (DAKO), and mounted in permanent medium (Fisher Scientific, Suwannee, 
GA). 
 
 
3.2.12    In vitro study of effect of pH on topotecan lactone and carboxylate  
  transport by BCRP 
 
Saos2-BCRP or Saos2-pcDNA cells (1 X 106) were maintained in regular DMEM 
media (10% FBS, 1% L-glutamine) in 10 cm2 dishes for 16 hours at 37°C. The media 
was carefully aspirated and the cells were washed twice with PBS (pH 6 or 8). For 
topotecan treatment at pH 6, 4.5 μl of 1 mg/ml topotecan in DMSO was diluted in 9 ml 
pH 6 PBS (at 37°C). For topotecan treatment at pH 8, 45 μl of 0.1 mg/ml topotecan in 
0.4N Borax solution was diluted in 9 ml pH 8 PBS (at 37°C). The prepared topotecan 
treatment solution (8 ml) was added to each 10 cm2 dish.  The cells were incubated with 
topotecan solution for 1 minute or 30 minutes at 37°C without CO2. Treatment media 
(200 μl) was removed and placed into 800μl cold methanol for topotecan extraction to 
determine the drug concentration left in the media. The plate was washed once with 5 ml 
cold PBS at the appropriate pH (6 or 8). PBS (1 ml) at either pH 6 or 8 was added into the 
dishes and the cells were detached using a cell scraper. The cells were then lysed by 
sonication for 10 seconds 3 times. The lysate (200 μl) was placed into 800 μl cold 
methanol for topotecan extraction to determine the intracellular drug concentration. The 
remainder of the lysate was used for protein quantification by using Bradford protein 
assay (Bio-rad #500-0006). 
 
 
3.2.13    Statistical analysis 
 
Statistical analysis was performed in Sigma Stat 3.1. Data were presented as 
mean±SD. For protein binding study, one-way ANOVA was performed. For vCSF study, 
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one way ANOVA was performed to determine the significance of between group 
differences, followed by bonferroni-corrected multiple comparisons of wild type with 
each knockout model. For ECF study, Kruskal-Wallis one-way ANOVA was performed 
(data doesn’t pass the normality test), followed by rank test to compare wild type and 
each knockout model. For gefitinib treatment study, student’s t test was performed to 
compare wild type and Mdr1a/b(-/-)Bcrp1(-/-). For lactone to carboxylate ratio study, one-
way ANOVA was performed to determine the significance of vCSF between group 
differences, followed by Bonferroni-corrected multiple comparisons of wild type with 
each knockout model. Student’s t test was performed to compare plasma and vCSF 
lactone to carboxylate AUC ratio within wild type or Mdr1a/b(-/-)Bcrp1(-/-). For pH effect 
study, student’s t test was performed to compare Saos2-BCRP and Saos2-pcDNA 
intracellular topotecan concentrations. 
 
 
3.3 Results 
 
 
3.3.1    Topotecan lactone protein binding 
 
Topotecan lactone protein binding was assessed in each of the mouse models used 
in this study, including FVB, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)/Bcrp1(-/-). The 
topotecan lactone unbound fractions were determined to be 30.1±1.0%, 29.2±2.7%, 
30.9±2.2%, and 27.5±1.9%, respectively. One-way ANOVA analysis showed no 
significant difference among these results (p=0.10).  
 
 
3.3.2    Bcrp1 and P-gp enhance topotecan penetration into ventricular CSF 
 
To investigate the relative contribution of Bcrp1 and P-gp on topotecan 
penetration into ventricular CSF (i.e., through blood CSF barrier), FVB wild type and 
three targeted mutation mouse models (Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-)) 
were used. A microdialysis probe was placed in the lateral ventricle of the mouse model 
as described above, and the probe location was verified with postmortem histology 
examination as depicted in (Figure 3-1A). After a single 4 mg/kg topotecan i.v. bolus 
injection, the vCSF to plasma ratio of unbound topotecan lactone was calculated for each 
animal. The vCSF to plasma AUC ratios (AUCu,vCSF/AUCu,plasma) were determined as 
2.85±0.14, 2.30±0.12, 1.50±0.05, 0.85±0.05 for FVB, Mdr1a/b(-/-), Bcrp1(-/-), and 
Mdr1a/b(-/-)/Bcrp1(-/-), respectively (Figure 3-2). The in vivo probe recoveries were 
8.1±2.4%, 7.1±1.1%, 7.5±1.5% and 6.0±0.6%, respectively. The CLin/CLout at the blood 
CSF barrier, determined by compartmental analysis, agreed well with the AUC ratio 
determined by noncompartmental analysis (Table 3-1).  
 
 
 50
 P 
LV 
P 
LV 
B A 
 
 
Figure 3-1  Microdialysis probe track in lateral ventricle or parenchymal tissue. 
 
(A). Saggital section of probe track (P) insertion into the lateral ventricle (LV). (B). 
Coronal section of probe track insertion into the brain parenchyma. 
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Figure 3-2  Topotecan lactone penetration into vCSF in various mouse models at 
one dose of topotecan 4mg/kg i.v. bolus. 
 
Individual representative unbound topotecan lactone concentration-time plots in vCSF 
(□) and plasma (■) in FVB (A), Mdr1a/b(-/-) (B), Bcrp1(-/-) (C) and Bcrp1/Mdr1a/b(-/-) (D). 
(E). vCSF to plasma AUC ratio of unbound topotecan lactone in various models. (One 
way ANOVA, F=351, P<0.05; Bonferroni-corrected multiple comparison between WT 
and each knockout model, *P<0.05)
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Table 3-1  Noncompartmental (AUC ratio) and compartmental analysis 
(CLin/CLout) for brain (CSF or ECF) to plasma AUC ratio of unbound topotecan 
lactone in various mouse models. 
 
  vCSF  ECF 
Mouse model  AUC ratio CLin/CLout  AUC ratio CLin/CLout 
Topotecan 4mg/kg       
WT  2.85 ± 0.14 (n=6) 3.01 ± 0.15  0.35 ± 0.04 (n=5) 0.36 ± 0.06 
Mdr1a/b(-/-)  2.30 ± 0.12 (n=4) 2.57 ± 0.17  N/A N/A 
Bcrp1(-/-)  1.50 ± 0.05 (n=3) 1.59 ± 0.16  0.35 ± 0.01 (n=3) 0.42 ± 0.06 
Bcrp1/Mdr1a/b(-/-)  0.86 ± 0.05 (n=5) 0.86 ± 0.04  0.81 ± 0.04 (n=3) 0.89 ± 0.07 
       
Topotecan 4mg/kg +       
Gefitinib 200mg/kg       
WT  1.15 ± 0.16 (n=3) 1.25 ± 0.14  0.63 ± 0.03 (n=3) 0.74 ± 0.14 
Bcrp1/Mdr1a/b(-/-)  1.10 ± 0.14 (n=3) 1.13 ± 0.13  0.95 ± 0.02 (n=3) 1.08 ± 0.03 
  
 53
3.3.3    Bcrp1 and P-gp decrease topotecan penetration into brain ECF 
 
Using a microdialysis sampling technique, the relative contribution of Bcrp1 and 
P-gp on topotecan penetration into brain ECF was assessed in transporter deficient mouse 
models.  As with the ventricular CSF studies, the location of the probe was verified with 
postmortem histology examination as depicted in Figure 3-1B. The ECF to plasma AUC 
ratios (AUCu,ECF/AUCu,plasma) of unbound topotecan lactone were determined as 
0.35±0.04, 0.35±0.01, and 0.81±0.04 for FVB, Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-), 
respectively (Figure 3-3). The in vivo probe recoveries were 8.5±2.4%, 5.4±0.6%, and 
4.3±0.2%, respectively. The topotecan lactone ECF concentrations in the Mdr1a/b(-/-) 
were at the lower limit of quantitation of the assay, so it was not possible to report an 
ECF to plasma AUC ratio (Leggas et al., 2004c; Zhuang et al., 2006). The CLin/CLout 
across the blood brain barrier determined by compartmental analysis agreed with the 
AUC ratio as estimated by the noncompartmental analysis (Table 3-1). 
 
 
3.3.4    Differential regulatory effects of gefitinib on topotecan penetration into 
vCSF and ECF 
 
To modulate the effect of active transporters on topotecan CNS penetration, the 
tyrosine kinase inhibitor gefitinib was administered to FVB and Mdr1a/b(-/-)Bcrp1(-/-) 
mice one hour prior to the topotecan dose.  After gefitinib pretreatment, similar topotecan 
lactone vCSF penetration (i.e., AUCu,vCSF/AUCu,plasma) was determined in FVB 
(1.15±0.16) and Mdr1a/b(-/-)Bcrp1(-/-)  mice (1.1±0.14) (see Figure 3-4A, 3-4B), These 
values were not significantly different (Student’s t test, p=0.27). These results suggest 
gefitinib fully inhibits Bcrp1 and P-gp function at the blood CSF barrier.  
 
These results were compared with the effect of gefitinib on topotecan lactone ECF 
penetration. In FVB mice, gefitinib pretreatment led to a topotecan lactone ECF 
penetration (e.g., AUCu,ECF/AUCu,plasma) of  0.63±0.03  (Figure 3-4C), which increased to 
0.95±0.02 in Mdr1a/b(-/-)Bcrp1(-/-) mice (Student’s t test, p<0.05) (Figure 3-4D). Thus, 
gefitinib may exert effects on Bcrp1 and P-gp function to different degrees at the blood 
brain barrier than at the blood CSF barrier. 
 
 
3.3.5    Preferential disposition of topotecan lactone in vCSF 
 
As Bcrp1 was identified as the primary transport protein responsible for topotecan 
penetration into ventricular CSF, the preference for unbound topotecan lactone and 
carboxylate was further studied.  First, the vCSF carboxylate AUC value was calculated 
for FVB and transporter deficient mouse models. The vCSF lactone to carboxylate AUC 
ratio (AUClactone,vCSF/AUCcarboxylate,vCSF) was determined as 5.7±0.8, 3.9±0.6, 3.6±0.5, and 
0.8±0.2 in FVB, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-), respectively (Figure 3-
5). Correspondingly the plasma lactone to carboxylate AUC ratio was 1.24±0.38 in FVB 
and 0.95±0.28 in Mdr1a/b(-/-)Bcrp1(-/-). These results suggested the higher lactone 
penetration into the vCSF cannot be attributed to the plasma lactone level  
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Figure 3-3  Topotecan lactone penetration into brain ECF in various mouse 
models at one dose of topotecan 4mg/kg i.v. bolus. 
 
Individual representative unbound topotecan lactone concentration-time plots in ECF (∆) 
and plasma (▲) in FVB (A), Bcrp1(-/-) (B) and Bcrp1/Mdr1a/b(-/-) (C). D, brain ECF to 
plasma AUC ratio of unbound topotecan lactone in various models. (Kruskal-Wallis one 
way ANOVA, P<0.05; Each knockout model was compared with WT, *P<0.05) 
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Figure 3-4  Regulatory effect of gefitinib on topotecan penetration into brain ECF 
or vCSF at one dose of topotecan 4mg/kg i.v. bolus and gefitinib 200mg/kg oral 
gavage pretreatment. 
 
Individual representative unbound topotecan lactone concentration-time plots in vCSF 
(A, B; □), ECF (C, D; ∆) and plasma (■,▲) with oral gefitinib pretreatment in FVB (A, 
C) and Bcrp1/Mdr1a/b(-/-) (B, D). E, Brain (vCSF or ECF) to plasma AUC ratio of 
unbound topotecan lactone in FVB and Bcrp1/Mdr1a/b(-/-). (Student’s t-test, WT 
compared with Bcrp1/Mdr1a/b(-/-), *P<0.05)
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Figure 3-5  vCSF lactone to carboxylate AUC ratio of unbound topotecan. 
 
vCSF (black column) lactone to carboxylate AUC ratio of unbound topotecan were 
determined in various mouse models and compared with the plasma lactone to 
carboxylate AUC ratio of unbound topotecan. (For plasma group, Bcrp1/Mdr1a/b(-/-) was 
compared with WT, student’s t-test. For vCSF group, one way ANOVA, F=51.8, P<0.05; 
Bonferroni-corrected multiple comparison between each knockout model and WT, 
*P<0.05)
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but rather to a consequence of active transport across the BCB. This would also suggest 
that Bcrp1 and P-gp transport the lactone form more effectively than the carboxylate 
form. 
 
 
3.3.6    Saos2-BCRP cells preferentially transport topotecan lactone 
 
To assess if BCRP will preferentially transport topotecan lactone or carboxylate, 
Saos2-BCRP cells were incubated with topotecan at different pH values to shift the 
distribution of lactone and carboxylate forms. At pH 6 after 1 min incubation of 
topotecan lactone, the intracellular topotecan lactone concentration was determined as 
0.063±0.01ng/μg protein in Saos2-pcDNA and 0.043±0.005ng/μg protein in Saos2-
BCRP (p<0.05, Student’s t-test). Similarly after 30 min incubation the intracellular 
topotecan lactone concentration was determined as 0.039±0.003ng/μg protein in Saos2-
pcDNA and 0.026±0.0043ng/μg protein in Saos2-BCRP (p<0.05, Student’s t-test). 
Topotecan carboxylate was not detected at pH 6 (Figure 3-6A, 3-6B). At pH 8 after 1 
min incubation of topotecan carboxylate, the intracellular topotecan carboxylate 
concentration was determined as 0.03±0.003 ng/μg protein in Saos2-pcDNA and 
0.028±0.04ng/μg protein in Saos2-BCRP (p=0.6, Student’s t test). Similarly after 30 min 
incubation the intracellular topotecan carboxylate concentration was determined as 
0.02±0.007ng/μg protein in Saos2-pcDNA and 0.02±0.002ng/μg protein in Saos2-BCRP 
(p=0.9 Student’s t test). Topotecan lactone was not detected at pH 8 (Figure 3-6C, 3-6D). 
These results demonstrated that BCRP preferentially transports the lactone form but not 
the carboxylate form of topotecan in vitro. 
 
 
3.4 Discussion 
 
The active transport mechanisms that control topotecan CNS penetration and 
pharmacokinetics in vivo are not clearly described. In this study, by using ABC 
transporters-targeted mutation mouse models, microdialysis sampling technique in 
discrete brain compartments and pharmacokinetic modeling, we demonstrated the 
differential action of Bcrp1 and P-gp in topotecan brain penetration through the CNS 
barriers: on one hand, they enhance topotecan accumulation into the CSF through their 
effect on the BCB; on the other, they restrict parenchymal brain topotecan exposure by 
their role as efflux transporters in the BBB. 
 
P-gp and Bcrp1 have been recently reported by Tellingen et al to work together in 
constraining topotecan brain penetration (de Vries et al., 2007). In their study., whole 
brain tissue homogenates of knockout mice (Mdr1a/b(-/-), Bcrp1(-/-), Mdr1a/b(-/-)Bcrp1(-/-), 
and Mrp4(-/-)) receiving topotecan were analyzed, showing that both P-gp and BCRP, but 
not MRP4, limit topotecan concentration in brain homogenates (de Vries et al., 2007). 
Although they obtained significant differences in topotecan penetration between animal 
groups depending on the presence or absence of ABC transporters and the inhibitor 
elacridar, the sampling technique they used is, by itself, a potential source of misleading 
results. In fact, their samples represent a mixture of three compartments found in the  
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pH 8, 1minute
 
 
 
Figure 3-6  pH effect on topotecan lactone and carboxylate transport by BCRP. 
 
Saos2-pcDNA (black column) and Saos2-BCRP (white column) cells were incubated 
with topotecan solution prepared in either pH 6 (A and C) or pH 8 (B and D) for 1 minute 
(A and B) or 30 minutes (C and D). After incubation the medium was removed and the 
intracellular concentration of topotecan lactone or carboxylate was determined.  
(Student’s t-test, *P<0.05). 
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brain, the CSF compartment (regulated by the BCB), the ECF compartment of brain 
parenchyma (regulated by the BBB), and the vascular compartment (separated from the 
other two compartments by both the BBB and the BCB). We and others have recently 
reported on the differential accumulation of drugs in these three compartments (Stain-
Texier et al., 1999; Zhuang et al., 2006). Remarkably, Stain-Texier et al. found 
sharpdifferences among the results obtained by analyzing morphine-6-glucoronide in 
brain ECF (sampled using microdialysis), CSF (sampled by puncture aspiration) or whole 
brain tissue (homogenates), determining a high accumulation of this morphine metabolite 
in brain ECF that could not have been determined by the brain homogenate technique. 
Similarly, we recently reported a differential accumulation of topotecan in cerebral 
compartments of FVB mice treated with gefitinib: increased concentrations in ECF and 
decreased in vCSF (Zhuang et al., 2006). 
 
The homogenate method used by Tellingen et al was unable to assess another two 
key parameters in topotecan pharmacokinetics: 1) bound and unbound drug fractions, and 
2) topotecan lactone-to-carboxylate ratio. The last question is especially relevant since 
even though simple HPLC methods are available to analyze topotecan and carboxylate 
forms simultaneously, in the mentioned study the samples were acidified to transform 
topotecan in the lactone form (de Vries et al., 2007). In contrast, by using the 
microdialysis technique we were able to accomplish with the challenging task of 
analyzing simultaneously both topotecan carboxylate and lactone unbound concentrations 
in the brain parenchymal ECF and the ventricular CSF. The technical difficulty of placing 
the probe precisely into the mouse lateral ventricle for vCSF sampling was overcome by 
a modified surgical procedure that takes advantage of the conventional features of a 
stereotaxic instrument and the tridimensional interpretation of the previously established 
knowledge on the mouse brain anatomy (Shen et al., 2008). The procedure allowed a 
continuous sampling in awake animals, defining individual pharmacokinetic profiles and 
reducing the number of laboratory animals employed in the study. 
 
After evaluating the plasma protein binding of lactone topotecan in our mouse 
models, vCSF to plasma AUC ratios of unbound topotecan lactone could be determined, 
serving as an invaluable indicator for drug penetration through BCB (Hammarlund-
Udenaes et al., 1997; Wong et al., 1993). By comparing the AUC ratios of the knockout 
mouse models to that of FVB wild type, the relative role of Bcrp1 and P-gp in topotecan 
vCSF penetration could be clearly defined. The results suggest that Bcrp1 plays a major 
role (AUC ratios were 1.5 vs 2.85 in Bcrp1(-/-) and FVB mice, respectively) and P-gp 
plays a relatively minor role (AUC ratios were 2.3 vs 2.85 in Mdr1a/b(-/-) and FVB mice, 
respectively) in enhancing topotecan penetration in the vCSF. The results also indicate 
there was no apparent functional redundancy between Bcrp1 and P-gp at BCB as 
deficiency of each protein caused corresponding reduced topotecan penetration. 
Furthermore, the relatively low AUC ratio (0.85) found in the Bcrp1/Mdr1a/b(-/-) model 
suggests that other efflux mechanisms may be involved. This is in agreement with our 
previous finding that MRP4 restricts topotecan vCSF penetration (Leggas et al., 2004a). 
In Bcrp1/Mdr1a/b(-/-) model the unbound topotecan concentrations in vCSF were 
maintained higher than in plasma in later drug elimination phase (Figure 3-2D). This 
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suggests in addition to Bcrp1 and P-gp there exist other mechanisms taking up drug from 
blood to vCSF.  
 
In contrast, the role of Bcrp1 or P-gp in BBB penetration cannot be defined 
separately as well as in BCB. In the Mdr1a/b(-/-) model Bcrp1 mRNA of cerebral 
microvessels was reported to be upregulated by 3 times (Cisternino et al., 2004).  This is 
also substantiated by the stronger Bcrp1 immunohistochemical staining in Mdr1a/b(-/-) 
than the FVB wild type mice (Figure 3-7). Although Tellingen et al. reported the Bcrp1 
protein level was not changed in this model by using western blot from brain 
homogenate, it is highly probable the protein expression alteration at microvessels was 
masked by brain tissues (de Vries et al., 2007). Thus the Mdr1a/b(-/-) model cannot be 
used reliably to verify the P-gp role in vivo in current experimental settings. In the 
Bcrp1(-/-) model, although there has been no report of upregulation of any compensatory 
mechanism, the ECF to plasma AUC ratio was determined as 0.35±0.01, which was 
comparable with FVB (0.35±0.04). This result agreed with what Tellingen et al. reported 
that no penetration difference has been found between Bcrp1(-/-) and wild type (de Vries 
et al., 2007). However Bcrp1 and P-gp together play a major role in restriction of 
topotecan penetration through BBB. This was substantiated by the ECF to plasma AUC 
ratio of unbound topotecan lactone (0.81±0.04) in the Bcrp1/Mdr1a/b(-/-) model. Similar 
to the situation in vCSF, besides Bcrp1 and P-gp, other mechanism(s) taking up drug 
from blood to ECF may be involved in the topotecan ECF penetration (Figure 3-3C).  
 
With clear understanding of the mechanisms (e.g. Bcrp1 and P-gp) that regulate 
topotecan CNS penetration through BCB and BBB we further investigated how these 
mechanisms can be modulated by a tyrosine kinase inhibitor, gefitinib. FVB and 
Bcrp1/Mdr1a/b(-/-) mouse models were used for the investigation. Our previous studies 
have demonstrated that gefitinib increased oral absorption and decreased systemic 
clearance of topotecan (Leggas et al., 2006; Stewart et al., 2004b). In the current study we 
are particularly interested in the role of gefitinib on modulating BBB and BCB. The 
rationale is if gefitinib fully inhibited Bcrp1 and P-gp function at BBB or BCB we would 
see the same AUC ratios in FVB and Bcrp1/Mdr1a/b(-/-) mice. At BCB with oral gefitinib 
pretreatment, the AUCu,vCSF/AUCu,plasma was 1.15±0.16 in FVB and 1.10±0.14 (p 
value=0.88) in Bcrp1/Mdr1a/b(-/-) which suggested gefitinib fully inhibited Bcrp1 and P-
gp function.  However at BBB  AUCu,ECF/AUCu,plasma was determined as 0.63±0.03  in 
FVB and 0.95±0.02 Bcrp1/Mdr1a/b(-/-) (p value<0.001), which suggested gefitinib cannot 
fully inhibit Bcrp1 and P-gp function at BBB (see Appendix for more strict reasoning). 
 
As mentioned above, both vCSF and ECF studies in Bcrp1/Mdr1a/b(-/-) model 
(Figure 3-2D, 3-3C, 3-4B, 3-4D) have suggested there are other ATP dependent and 
independent mechanisms involved in topotecan transport across BCB and BBB. Recently 
a SLC22 family protein OAT3 has been shown to play a role in the rat renal tubular 
secretion of topotecan (Matsumoto et al., 2007). This protein is known to be expressed on 
the apical side of choroid plexus at BCB and basolateral side of endothelial cells at BBB 
(Loscher and Potschka, 2005a; Nagata et al., 2002). In addition SLC21 family proteins 
(organic anion transporting polypeptides, OATPs) are also widely expressed on BBB and 
 
 
A B 
 
Figure 3-7  IHC staining of Bcrp in FVB and Mdr1a/b(-/-). 
 
Immunohistochemical staining of Bcrp1 at brain capillary vessels (arrows) in FVB wild 
type 100X (A) and Mdr1a/b(-/-) 100X (B). The staining was stronger in Mdr1a/b(-/-) than in 
wild type. 
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BCB. For examples, rat Oatp2 is expressed on both apical and basolateral sides of 
capillary endothelial cells and also expressed on the basolateral side of choroid plexus 
epithelial cells (Gao et al., 1999). Mouse Oatp3 is localized at the apical side of choroid 
plexus epithelial cells (Ohtsuki et al., 2004). Although these transporters are not reported 
to transport topotecan directly it is reported the human counterpart OATP-C can uptake 
another camptothecin analog, irinotecan and its active metabolite SN-38 (Nozawa et al., 
2005). Taken together, these uptaking transporters can work with or against ABC 
transporters, depending on their subcellular localizations, to regulate drug penetration 
into the CNS. For example, the basolateral localized Oatp2 at BCB can work with Bcrp1 
and P-gp to enhance topotecan penetration into CSF; on the contrary apical localized 
OAT3 at BCB can work against Bcrp1 and P-gp but with MRP4 to restrict topotecan 
penetration. The effect of these uptaking mechanisms becomes significant especially 
when the major efflux transporters, Bcrp1 and P-gp, were absent (Figure 3-2D, 3-3C, 3-
4B, 3-4C). Despite involvement of other transporters, the Bcrp1 and P-gp mediated 
mechanisms still dominated topotecan transport across BBB and BCB. 
 
The clear understanding of transporting mechanisms for the drugs intended to 
treat brain tumors and other CNS diseases has significant clinical relevance (Kaddoumi et 
al., 2007). Only with such knowledge can an appropriate and effective modulation 
strategy be identified to avoid the drawback of drug penetration. Furthermore, brain 
penetration should also be considered even for the drugs not meant to treat brain tumors. 
This is largely because the drugs with poor brain penetration tend to make the brain a safe 
heaven for metastatic tumor cells. It is roughly estimated 10% - 30% of cancer patients 
eventually developed brain metastasis (Palmieri et al., 2007; Patel and Mehta, 2007). 
Therefore, clearly defining the CNS penetration property of a new drug deserves more 
attention in the drug development process. 
 
  
Chapter 4. Topotecan Penetration in an Intracranial Human Glioblastoma (U-87) 
Mouse Model 
 
 
4.1 Introduction 
 
Central nervous system (CNS) tumors that cannot be managed by surgery and 
radiation will require adjuvant chemotherapy. However the role of chemotherapy in 
treatment of CNS tumors in a clinical setting is not clear. For example, camptothecin 
analogs (e.g. topotecan) are a promising class of agents that has demonstrated potent anti-
tumor activity in preclinical CNS tumor xenograft studies (Hare et al., 1997; Houghton et 
al., 1995). However in clinical studies, only a modest response was observed in 
medulloblastoma patients, and very poor response was observed in malignant glioma 
patients (Nicholson et al., 2007; Stewart et al., 2004a; Chintagumpala et al., 2006). One 
probable reason is the presence of the blood brain barrier (BBB), which restricts the CNS 
penetration of the chemotherapeutic agents.  
 
Drug CNS penetration is determined by multiple factors including drug 
physiochemical properties, drug protein binding fraction, and drug influx or efflux 
transporter systems. Our previous work demonstrates topotecan penetration into normal 
brain parenchymal tissue was restricted by the efflux ABC transporters (e.g. Bcrp1 and P-
gp) located at BBB (Zhuang et al., 2006). The pathological conditions of the tumor itself 
add another layer of complexity to understanding topotecan penetration into CNS tumors. 
 
The CNS tumor BBB is often referred to as blood brain tumor barrier (BTB). 
BTB has distinct properties from normal BBB. First, many tight junction proteins (e.g. 
ZO-1, occludin and claudin) are downregulated at BTB (Sawada et al., 2000; Liebner et 
al., 2000; Papadopoulos et al., 2001). Second, the vasculature in solid tumors usually 
appears in abnormal morphology, which results in a torturous and irregular vessel lumen 
(Baluk et al., 2005). Third, there exists active angiogenesis activity in tumor (Ferrara, 
2004; Nabors et al., 2001; Strugar et al., 1995; Weindel et al., 1994). The effects of all 
these uncommon activities in tumor on drug delivery can become quite complicated and 
unpredictable. For example, the disregulated tight junction and active angiogenesis 
activities produce a more permeable blood vessel, which might increase drug delivery 
(Devineni et al., 1996a; Dukic et al., 2004). On the other hand, the abnormal blood vessel 
reduces blood flow, which could decrease drug delivery. Furthermore, a more permeable 
vasculature might cause increased interstitial fluid pressure (IFP), which resists drug 
delivery from blood to tissue. In a rat model, normalizing the tumor blood vessel 
increased topotecan delivery to neuroblastoma (Dickson et al., 2007). However the same 
strategy (normalizing the tumor blood vessel) does not seem to work for CNS tumor 
(Devineni et al., 1996b; Claes et al., 2008). 
 
Although topotecan penetration studies have been done in other tumors (e.g. 
neuroblastoma) (Dickson et al., 2007), the data cannot be directly extrapolated for 
gliomas due to the distinct features of CNS tumors (e.g. blood brain barrier). A clearer 
understanding of drug disposition in the tumor itself is critical for developing effective 
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therapy. If topotecan concentrations in tumor can be measured, a model can then be 
constructed to relate the drug tumor exposure to plasma exposure. Based on that model, a 
target exposure level can be reached by controlling the plasma exposure, which is 
clinically more convenient. For example, in a pediatric medulloblastoma trial, when 
topotecan lactone CSF concentrations were measured (medulloblastoma has extensive 
access to CSF), a three-compartment model was constructed to relate CSF concentrations 
to plasma concentrations. With the model, a CSF target exposure (>1 ng/ml for 8 hr) 
determined through preclinical study (Zamboni et al., 1998) can be reached by 
maintaining a  plasma exposure between 120 and 160 ng/ml·hr (Stewart et al., 2004a). 
The clinical outcome was also encouraging because 28% of the patients responded to the 
therapy and 47% of the patients had their diseases stabilized (Stewart et al., 2004a).  
Currently however, reliable topotecan disposition data in gliomas is still lacking. 
 
It would be of great clinical interest to define the topotecan penetration through 
BTB of gliomas. Our hypothesis is the pathological conditions in glioma will increase 
topotecan penetration into tumor tissue compared with normal brain. Thus, the objective 
of this study is to provide insights to the topotecan disposition in a mouse glioma (U-87) 
model. 
 
 
4.2 Methods and materials 
 
 
4.2.1    Drugs and reagents 
 
Topotecan (HycamtinTM) was obtained from GlaxoSmithKline (Philadelphia, PA) 
and prepared in sterile water at a concentration of 1 mg/ml. HPLC grade reagents are 
obtained from Fisher Scientific (Pittsburgh, PA) or Sigma-Aldrich (St. Louis, MO). 
 
 
4.2.2    Tumor cell line 
 
Firefly luciferase labeled U-87 human glioblastoma cells were kindly provided by 
Dr. Davidoff (Department of Surgery, St. Jude Children’s Research Hospital). Cells were 
cultured in DMEM medium (10-013-CM, Mediatech, Herndorn, VA) supplemented with 
10% fetal bovine serum (SV30014.03, Hyclone, Logan UT), 1% L-glutamine (13533, 
Invitrogen, Grand Island, NY) and 0.4mg/ml G418 (10131-035, Invitrogen, Grand Island, 
NY) in a humidified incubator with 5% CO2 at 37ºC. 80%-90% confluent cells were 
collected, counted and resuspended in Matrigel (356234, BD Biosciences, San Jose, CA) 
to prepare a cell suspension of 1x105 cells/µl for tumor inoculation. 
 
 
4.2.3    Animal 
 
CD-1 nude female mice were purchased from Charles River Laboratories 
(Wilmington, MA). The mice were maintained on a 12 hour light/dark cycle with free 
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access to food and water. After surgery, the mice were housed individually in cages. All 
procedures were approved by St. Jude Institutional Animal Care and Use Committee and 
in accordance with the Association for Assessment and Accreditation of Laboratory 
Animal Care (AALAC). 
 
 
4.2.4    Intracranial tumor inoculation 
 
CD-1 nude female mice (25-30 g) were anaesthetized with ketamine (Abbott 
Laboratories, Chicago IL) /xylazine (Butler Company, Columbus, OH) at the dosage of 
one 0.1 ml intraperitoneal injection followed by two 0.05 ml intramuscular injections. 
The skull was secured in a stereotaxic apparatus. A small piece of scalp was removed to 
expose the top of skull. A burr hole was drilled (AP: -2mm, ML: 1.5mm, DV: -2mm, 
relative to bregma point on a flat skull). Two additional small holes were drilled for bone 
anchor screws a few millimeters away from the burr hole. A 25µl Hamilton syringe (14-
813-21, Fisher) with a 26-gauge needle (14-816-212A, Fisher) was used to implant tumor 
cells.  The syringe was lowered down 2 mm into the brain parenchyma through the burr 
hole drilled previously. 2.5 µl of tumor cells in Matrigel was slowly injected into the 
brain. After 1 minute, the syringe was retrieved by 1 mm and another 2.5 µl of tumor 
cells was injected. After 1 minute the syringe was slowly removed. Total 5x105 cells in 5 
µl Matrigel were injected. 
 
 
4.2.5    Microdialysis guide cannula implant 
 
Three different groups of study were conducted. 1) For microdialysis study in 
tumor tissue, a guide cannula (MD-2255, Bioanalytical Systems, West Lafayette, IN) was 
inserted (2 mm deep) through the same burr hole as the tumor implant right after tumor 
inoculation. 2) For microdialysis in contralateral normal tissue study, another burr hole 
was drilled (1.5 mm lateral to the left, 2 mm posterior) for guide cannula implant. 3) For 
microdialysis study in nontumor bearing mice, only the matrigel without tumor was sham 
inoculated. Dental cement was applied to seal the scalp opening and support the anchor 
screws. Animals were returned to cages and observed for survival.   
 
 
4.2.6    Bioluminescence imaging 
 
Luciferin (69000, Xenogen, Hopkinton, MA) was prepared in water at a 
concentration of 15 mg/ml and administered to animals through i.p. (giving 3 mg per 
mouse).  At 4 minutes post-injection, mice were anesthetized using isoflurane and placed 
into the Xenogen IVIS-200 imaging system where anesthesia was maintained for the 
duration of the scan (no longer than 5 min).  After scanning, animals were allowed to 
recover under observation and supplemented with oxygen where necessary. The total flux 
(photons/second) from the whole tumor imaged area was used as the bioluminescence 
signal.  
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4.2.7    Correlation of tumor growth with bioluminescence signal 
 
24 CD-1 nude female mice were inoculated with luciferase labeled U-87 cells on 
day 1 as described above (without guide cannula). On day 7, 9, 11, 13, 15, 17 after tumor 
implant, three or four mice were randomly selected and measured for bioluminescence 
signals as described above. After imaging the mice were euthanized immediately and the 
whole head was removed and fixed in 10% neutral formalin for 48 hours.  The mouse 
brain was then excised and the tumor was measured on three dimensions (X, Y and Z). 
The tumor volume was calculated by using an ellipsoid equation (tumor 
volume=X*Y*Z*0.5233). The tumor volume was correlated to the bioluminescence 
signal. 
 
 
4.2.8    Microdialysis procedure 
 
CD-1 nude mice inoculated with tumor were monitored and imaged on day 12 or 
13 after tumor implant. Mice with the bioluminescence signals within the range of 1x108 
to 8x108 p/s were used for microdialysis study. The microdialysis procedure and probe 
calibration was previously reported in detail (Leggas et al., 2004c; Zhuang et al., 2006). 
Briefly, on the day of an experiment, a microdialysis probe (MD-2211, Bioanalytical 
Systems, West Lafayette, IN) was flushed with blank artificial CSF (aCSF, NaCl 
148mM, KCl 4mM, MgCl2 0.8mM, CaCl2 1.4mM, Na2HPO4 1.2mM, NaH2PO4 0.3mM 
and Dextrose 5mM, pH adjusted to 7.4). The probe was inserted through the cannula into 
the brain, and the aCSF perfusion rate was set at 0.5 μl/min. The probe was allowed to 
equilibrate in vivo for 1 hour. Topotecan (4 mg/kg) was administered by i.v. bolus 
through the lateral tail vein. The dialysate samples were directly loaded onto a sample 
loop (2 μl) and analyzed through an online microbore HPLC system (Leggas et al., 
2004c). Probe recovery was determined using the in vivo retrodialysis method after each 
experiment was completed. During the microdialysis period, three plasma samples were 
collected from a mouse at 0.25, 1, and 3 hours after topotecan administration for plasma 
pharmacokinetic analysis (Zhuang et al., 2006).  
 
 
4.2.9    Histology 
 
At the completion of a microdialysis experiment, the animal was euthanized and 
the brain removed and fixed in 10% NBF for at least 48 hours.  The brain was then cut 
into coronal segments, dehydrated, cleared and embedded in a paraffin block.  Sections 
were cut on a microtome at 4 µm thickness and every tenth section was collected and 
stained with haematoxylin and eosin.  All sections from a given block were examined 
microscopically to verify the location of the microdialysis probe via the track in the tissue 
(Zhuang et al., 2006). 
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4.2.10    Noncompartmental analysis of brain pharmacokinetic data  
 
The pharmacokinetic analysis of topotecan lactone was performed for each mouse 
(Zhuang et al., 2006). Topotecan lactone concentrations in vCSF were corrected for the 
hydrolysis of topotecan lactone to the carboxylate that occurs in pH 7.4 artificial CSF as 
described previously (Leggas et al., 2004c). The AUC in vCSF from time 0 to infinity 
was estimated using the linear trapezoidal method with the addition of a residual area as 
depicted in Equation 4-1, 
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where Ci is the topotecan concentration in dialysate; Δt is the sample injection interval; 
Cn is the last measurable topotecan concentration; β is estimated by linear regression of 
the logarithm of the last 4-5 measurable concentrations.  
 
 
4.2.11    Protein binding 
 
Topotecan lactone protein binding was determined in plasma collected from CD-1 
nude tumor bearing mice. The approach was previously described (Zhuang et al., 2006). 
Briefly, topotecan lactone was added to the plasma to make a 500 ng/ml solution. Spiked 
plasma (0.5 mL) was added to a Centrifree YM-30 (Millipore Corporation, Billerica, 
MA) sample reservoir and centrifuged at 2000 g for 20 minutes. Topotecan was extracted 
from the protein and ultrafiltrate portion of the device, respectively, by adding 50 μL of 
sample immediately to 200 μL of cold methanol stored on dry ice. Samples were 
analyzed by an HPLC method as previously reported (Furman et al., 1996; Baker et al., 
1996). Topotecan lactone fraction unbound was calculated as amount of unbound 
topotecan lactone divided by total amount of topotecan lactone in plasma. 
 
 
4.2.12    Compartmental analysis of plasma pharmacokinetic data 
 
Plasma topotecan lactone concentration-time data were first corrected for plasma 
protein binding using an unbound factor. A population pharmacokinetic study was first 
performed to determine the population mean and variance for unbound topotecan lactone 
pharmacokinetic parameters as previously described (Zhuang et al., 2006). Then for each 
mouse, a two-compartment pharmacokinetic model was fitted to the plasma topotecan 
lactone concentration-time data using maximum a posteriori probability (MAP) Bayesian 
estimation as implemented in ADAPT II (D'Argenio and Schumitzky, 1979). 
Pharmacokinetic parameters determined included volume of central compartment (Vc), 
total elimination clearance (CLt), volume of peripheral compartment (Vp) and 
intercompartmental clearance (CLp).  Using these parameters, the unbound topotecan 
lactone concentrations in the plasma were simulated in ADAPT II. The area under the 
concentration-time curve from zero to infinity (AUC0→∞) for the unbound topotecan 
plasma was calculated by integration of the simulated concentration-time data from 
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model estimates.  A ratio of the brain AUC to unbound plasma topotecan lactone AUC 
was calculated and used as a measurement of topotecan vCSF penetration (Hammarlund-
Udenaes et al., 1997). 
 
 
4.2.13    Statistical analysis 
 
Statistical analysis was performed in Sigma Stat 3.1. One way ANOVA was 
conducted to determine the significance of between group differences. The difference 
was considered significant when p<0.05. 
 
 
4.3 Results 
 
 
4.3.1    Topotecan lactone protein binding  
 
Topotecan protein binding was assessed in the plasma collected from CD-1 nude 
tumor bearing mice. The topotecan lactone unbound fraction was determined 
27.0%±2.43. 
 
 
4.3.2    Tumor volume correlated to bioluminescence signal 
 
To assess the correlation between bioluminescence signal and tumor volume, 
tumor growth was monitored by measuring the bioluminescence signal indicated by total 
flux (photon/s). After completion of imaging, the tumor volume was measured and then 
correlated with bioluminescence signal. As shown in Figure 4-1, although the 
bioluminescence signal increased with the growth of tumor, a linear regression only 
produced a R2=0.47 Figure 4-2, which indicates the bioluminescence signal is not 
linearly correlated with tumor volume very well and was only used as a reference. 
 
 
4.3.3    Topotecan penetration is not statistically different in the U-87 tumor tissue  
from normal tissue 
 
Topotecan penetration was assessed in U-87 tumor tissue, normal tissue of non-
tumor bearing mice and contralateral normal tissue of tumor bearing mice. The probe 
placement was verified in the tumor or normal tissue as depicted in Figure 4-3. After one 
i.v. bolus 4mg/kg topotecan injection, the brain ECF to plasma AUC ratio of unbound 
topotecan lactone was determined as  0.68±0.32 (n=9), 0.82±0.47 (n=3) and 0.63±0.59 
(n=3) in tumor tissue, normal brain of non-tumor bearing mice and contralateral normal 
brain of tumor bearing mice Figure 4-4. No statistical difference was found between any 
groups (one way ANOVA, F=0.182, P=0.836). 
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Day 7 Day 13 Day 17
 
 
 
Figure 4-1 Tumor (U-87) growth monitored by bioluminescence. 
 
U-87 tumor was implanted on day 1. Tumor growth was monitored with bioluminescence 
imaging by randomly selecting 3 to 4 mice from total 24 mice. The signal strength 
increased from blue to red. The images on day 7, 13 and 17 after tumor implant were 
shown. 
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Figure 4-2 Correlation of tumor volume to bioluminescence signal. 
 
A linear regression was performed to correlate the bioluminescence signal (total flux p/s 
108) to tumor volume (mm3). 
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Figure 4-3 Microdialysis probe in tumor or normal brain. 
 
H&E staining of coronal section of probe insertion into tumor (A) or normal brain (B). 
Probe (P), lateral ventricle (LV), tumor tissue (T), normal brain (N). 
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Figure 4-4 TPT penetration in the U-87 tumor model of CD-1 nude mice. 
 
After one i.v. bolus 4mg/kg topotecan injection, the brain ECF to plasma AUC ratio of 
unbound topotecan lactone was determined in tumor tissue (Tumor), normal brain of non-
tumor bearing mice (Normal tissue) and contralateral normal brain of tumor bearing mice 
(Contralateral). (one way ANOVA, F=0.182, P>0.05) 
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4.4 Discussion 
 
Topotecan penetration in gliomas is not well understood. In this study, we 
constructed an orthotopic human glioblastoma (U-87) xenograft mouse model to gain 
insights into topotecan penetration into a glioma tumor model, which is primarily 
parenchymal tissue based. Our preliminary results suggest that topotecan penetration in 
U-87 glioma tumor tissue is not statistically different from normal brain. 
 
U-87 is a well established human glioblastoma cell line. It has often been used as 
a human glioma model (Claes et al., 2008; Nakatsu et al., 1997). The tumor line 
expresses several ABC transporters such as P-gp and MRP1(Rittierodt et al., 2004; Perek 
et al., 2005). Our previous study also suggested MRP4 might also be expressed in U-87 
(unpublished data). In the present study, U-87 was labeled with a firefly luciferase, which 
makes it possible to monitor the tumor growth with bioluminescence imaging in vivo.  
 
It is also recognized that U-87 grows in a self-contained fashion (Cretu et al., 
2005; Ozawa et al., 2002), which does not recapitulate the infiltrative feature of gliomas 
in clinic. This limitation has to be taken into account in the interpretation of drug 
penetration data obtained in U-87. 
 
Although topotecan penetration into normal brain tissue ECF was restricted by 
ABC transporters (e.g., Bcrp1 and P-gp) as described in Chapter 3, the overall effect of 
the presence of tumor on topotecan penetration is not clear. Straathof et al. first reported 
in a rat glioma (9L) model, topotecan concentrations in tumor were 20-fold higher than in 
normal brain tissue (Straathof et al., 1999). However, in that study the topotecan 
concentrations in tumor or normal brain were determined by tissue homogenate method. 
Furthermore the total concentrations rather than protein unbound concentrations were 
used. The conclusions based on these data could be misleading due to the limitations of 
the homogenate method, which included the drug that was bound to proteins (also 
discussed in Chapter 1).  
 
In the current study, by using intratumoral microdialysis the protein unbound 
topotecan concentrations were directly measured through an online microbore HPLC 
system. Plasma concentrations were corrected with a topotecan protein unbound fraction 
(0.27). The tumor to plasma AUC ratio of unbound topotecan lactone 
(AUCu,tumor/AUCu,plasma) serves a more reliable indicator for topotecan intratumoral 
penetration.  
 
Another anti-cancer drug methotrexate was reported to have a higher penetration 
in brain tumor than in normal brain by using intratumoral microdialysis (de Lange et al., 
1995; Devineni et al., 1996a; Dukic et al., 2004). Based on our data, topotecan apparently 
has a different disposition tendency in glioma. Thus it is strongly suggested that drug 
disposition in CNS tumors depend not only on tumor but also on drug properties. The 
penetration data from one drug cannot be extrapolated to another without care. 
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Unexpectedly, the normal brain to plasma AUC ratio of unbound topotecan 
lactone in CD-1 nude mice (0.82±0.47) appears much higher than in FVB mice 
(0.36±0.06, Chapter 3). It might be attributed to the position through which guide 
cannulas were implanted. Although the microdialysis probe was apparently in the 
parenchymal tissue, the position we selected in this study went through the lateral 
ventricle, which might cause CSF to leak into the microdialysis probe. For future study, a 
new position should be used to implant tumor and a guide cannula to rule out the 
possibility of CSF contamination. 
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Chapter 5. Summary and Future Directions 
 
 
Therapy for primary CNS tumors, especially malignant gliomas, still remains a 
major challenge. Failure of therapy could be attributed to multiple factors, which can be 
categorized into tumor intrinsic resistance, therapy related induced resistance, and 
inadequate drug delivery. Camptothecin analogs (e.g. topotecan and irinotecan) 
demonstrate potent anti-tumor activity including CNS tumors in animal xenograft 
models. However, the results of clinical trials with camptothecin analogs for CNS tumors 
are far from satisfactory. Although medulloblastoma patients responded modestly 
(Stewart et al., 2004a; Nicholson et al., 2007), malignant glioma patients responded 
poorly (Chintagumpala et al., 2006; Nicholson et al., 2007).  
 
A possible explanation for the discrepancy between the preclinical and clinical 
results is that in the subcutaneous xenograft tumor model, drug administration is 
associated with an increased drug delivery to the tumor sites.  This is compared with 
clinical studies where systemic drug delivery to intracranial tumor sites may be 
inadequate due to two well-known barriers in the brain, BBB and BCB. From the 
perspective of drug delivery, the BBB and the BCB regulate two distinct brain 
compartments; the ECF compartment of parenchymal tissues and the brain vCSF 
compartment respectively. After systemic administration, drugs must pass through at 
least one of these two barriers to gain access to the brain (Loscher and Potschka, 2005a). 
Included in these barriers are transporter proteins of the ATP binding cassette (ABC) 
family, including P-gp, MRP1, MRP2, MRP4, and BCRP (Ito et al., 2005b). These 
transporters play a role in drug resistance and results of several studies have shown that 
topotecan is a substrate for BCRP (Maliepaard et al., 1999b; Maliepaard et al., 2001b; Ito 
et al., 2005a), P-gp (Chen et al., 1991; Hendricks et al., 1992a), and MRP4 (Leggas et al., 
2004b). The distinct physiological and molecular properties of BBB and BCB could 
result in very different drug penetration into the two brain compartments (ECF or CSF) 
through these two barriers (Zhuang et al., 2006). Thus, it is necessary to investigate each 
compartment by separate experiments. Although some work has been published on the 
extent to which these barriers regulate topotecan CNS penetration, it would be of great 
clinical interest to gain a better understanding of how and to what degree this regulation 
occurs. 
 
Investigation of drug penetration into these compartments may be performed 
utilizing a microdialysis technique in the ventricular CSF or in ECF of brain parenchymal 
tissues. To date, most work using this technique has been done in a rodent model, 
primarily the rat.  It has not been common practice to use murine models for 
microdialysis studies as it poses a great deal of technical challenge to place microdialysis 
probe precisely into the mouse ventricle due to its small size and strain related variability 
in anatomy. However the traditional perpendicular probe insertion method used primarily 
in rats gives a very low success rate and poor reproducibility in murine models. Although 
we had previously developed a method to perform the microdialysis procedure in FVB 
mouse, but it was often associated with probe placement failure and side-effects (e.g., 
hemorrhage, inflammatory reactions) making interpretation of the results difficult.  We 
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are the first laboratory to study drug distribution in vCSF by using the CNS microdialysis 
technique in a murine model.  Since the current work requires the use of knockout mice, 
it is necessary to develop a more reliable probe placement procedure to precisely place 
the microdialysis probe into the ventricle with an acceptable success rate and fewer side 
effects.  
 
We developed a modified surgical procedure to implant a microdialysis probe to 
sample vCSF in FVB mice. The modification consisted of changes in the stereotaxic 
coordinates and insertion of the cannula and ultimately the probe at a 20 degree angle 
(Shen et al., 2008). Exact placement of the probe was confirmed using ultrasound (US), 
micro-computed tomography (CT), and histologic review of serial paraffin sections. 
Additionally, studies of topotecan CSF penetration in the FVB mouse were conducted. 
Unexpectedly with this modified procedure, the ventricular CSF to plasma AUC ratio of 
unbound topotecan lactone was greater than that previously reported using conventional 
methods (Shen et al., 2008). We speculate this is due to changes incorporated by the 
modified procedure that places the probe directly into the lateral ventricle allowing 
sampling of that discrete compartment. 
 
Next we applied this modified surgical procedure in the microdialysis studies to 
investigate the mechanisms that control topotecan penetration into brain ECF or vCSF. A 
differential topotecan penetration in two CNS compartments, the ventricular 
cerebrospinal fluid (vCSF) and brain parenchymal extracellular fluid (ECF) was 
determined in targeted mutation mouse models (Bcrp1(-/-), Mdr1a/b(-/-) and 
Bcrp1/Mdr1a/b(-/-)). After an intravenous (i.v.) bolus dose of 4mg/kg topotecan, unbound 
lactone vCSF penetration was defined by a vCSF to plasma area under the curve ratio 
(AUCu,vCSF/AUCu,plasma; mean ± SD) of 2.85±0.14, 2.3±0.12, 1.5±0.05 and 0.86±0.05 in 
FVB, Mdr1a/b(-/-), Bcrp1(-/-) and Bcrp1/Mdr1a/1b(-/-) mice, respectively. The penetration 
into the brain parenchyma, defined by the ECF to plasma AUC ratio 
(AUCu,ECF/AUCu,plasma) was determined as 0.35±0.04, 0.35±0.01 and 0.81±0.04 for FVB, 
Bcrp1(-/-) and Bcrp1/Mdr1a/b(-/-) mice, respectively. By co-administering the tyrosine 
kinase inhibitor gefitinib (200 mg/kg) to inhibit Bcrp1 and P-gp transporters, the 
AUCu,vCSF/AUCu,plasma  values significantly decreased to 1.15±0.16 in FVB mice and 
1.1±0.14 in Bcrp1/Mdr1a/b(-/-), while AUCu,ECF/AUCu,plasma ratios significantly increased 
to 0.63±0.03 in FVB and 0.95±0.02 in Bcrp1/Mdr1a/b(-/-). Interestingly, a preferential 
disposition of topotecan lactone over carboxylate was apparent in vCSF. The topotecan 
lactone to carboxylate AUC ratio in vCSF (AUClactone,CSF/AUCcarboxylate,CSF) was 
calculated as  5.69±0.83, 3.85±0.64, 3.61±0.46 and 0.78±0.19 in FVB, Mdr1a/b(-/-), 
Bcrp1(-/-) and Bcrp1/Mdr1a/b(-/-) mice, respectively. In contrast, in mouse plasma this 
lactone to carboxylate ratio did not change significantly between the mouse knockout 
strains. Taken together, our results 1) support a dominant role of Bcrp1 over P-gp in 
topotecan penetration through the blood CSF barrier (BCB), 2) suggest that Bcrp1 and P-
gp work similarly in constraining topotecan penetration through the blood brain barrier 
(BBB), and 3) determine, for the first time, that the lactone form is a preferred substrate 
for the ABC transporters as compared to the carboxylate. Our findings could be relevant 
for the improvement of pharmacological strategies to treat brain tumors. 
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Although this study was designed to evaluate topotecan CNS penetration, our 
long-term goal is to establish a model to determine the CNS penetration of any drug, and 
address research questions that are related to drug transport mechanisms. Such a model 
must include reliable surgical procedures to target distinct brain compartments (e.g., 
ventricles or parenchymal tissues), microdialysis sampling technique coupled with a 
sensitive bioanalytical method, proper animal models, and robust pharmacokinetic 
analysis method. This study was an example of successful application of such a model for 
topotecan CNS penetration.  
 
Once we had an understanding of the mechanisms that control topotecan CNS 
penetration under physiological conditions, we further investigated its penetration in the 
presence of tumor. A luciferase labeled human glioblastoma (U-87) mouse model was 
constructed and used in this study. This allowed the tumor growth to be monitored by 
measuring the bioluminescence signal. Our preliminary results suggest topotecan 
penetration in the U-87 tumor model was not really different from the normal brain. 
However this model might be biased due to the location of tumor inoculation, which went 
through the mouse lateral ventricle. Based on the knowledge obtained from Chapter 3, 
the leaking CSF might cause an overestimation of the drug penetration into brain 
parenchyma. Further investigation is necessary. 
 
Evidence has just started to accumulate that drug differential penetration into ECF 
from CSF may be a more universal phenomenon in more species. A Pfizer group reported 
that in rats an investigational new drug CP-615003 had a CSF-to serum ratio seven times 
as high as ECF-to serum ratio (Venkatakrishnan et al., 2007). An HIV-1 proteinase 
inhibitor nelfinavir, a P-gp substrate, was also reported to have distinct penetration into 
CSF from ECF in nonhuman primates. With co-treatment of a P-gp inhibitor zosuquidar, 
nelfinavir ECF concentrations were increased by 146-fold while the CSF concentrations 
were unaffected (Kaddoumi et al., 2007). Most recently it was reported that P-gp 
restricted loperamide penetration into ECF, but not in CSF, in a spontaneous canine P-
glycoprotein knockout model (Mealey et al., 2008). Thus, for future studies, the tumor 
inoculation position in the brain should be adjusted where a microdialysis probe does not 
have to go through the lateral ventricle. This is particularly important for drugs (e.g., 
topotecan) that have distinct penetration into ECF from CSF.  
 
Over the last decade many genetic manipulated mouse models have been 
generated to mimic human CNS tumors (e.g., medulloblastoma and glioblastoma) (Uziel 
et al., 2005; Romer et al., 2004; Lee et al., 2003). In addition to xenograft models, the 
mouse spontaneous tumor models are better alternatives to investigate drug penetration 
into the tumors. As spontaneous models offer an in vivo tumor environment with much 
less artificial effects, which are important for drug penetration studies.  
 
With appropriate tumor models, research questions with great clinical relevance 
can be addressed. For example, in clinical practice many CNS tumor patients also receive 
dexamethasone for controlling the brain edema (Nahaczewski et al., 2004). 
Dexamethasone (DEX), a synthetic glucocorticoid, binds to glucocorticoid receptor that 
is widely expressed intracellularly and regulates transcription of various genes involved 
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in glucose metabolism, cytochrome P450 drug metabolizing enzymes, drug transporters 
and immune response. Numerous studies have demonstrated DEX can enhance CYP3As 
expression in rodents (Anakk et al., 2003; Down et al., 2006; Wei et al., 2002; Huss and 
Kasper, 2000) and human (Moore et al., 2000; Pascussi et al., 2000b; Pascussi et al., 
2000a; Pascussi et al., 2001) through nuclear receptor PXR. DEX also regulates drug 
transporters expression and the pattern is more complicated. In a few early studies the 
effects of DEX treatment on P-gp are not consistent. A murine thymoma cell line was 
induced to overexpress P-gp by DEX (Bourgeois et al., 1993). In rat hepatocytes P-gp 
can only be weakly upregulated by DEX (Fardel et al., 1993). Later on it became clearer 
that the P-gp regulation by DEX could be cell and tissue specific. In primary normal rat 
hepatocytes DEX suppressed P-gp expression (Chieli et al., 1994; Schuetz et al., 1995) 
through a post-transcriptional mechanism. However in a rat hepatoma cell line H35 DEX 
activated P-gp transcription (Schuetz et al., 1995). A recent study in rats has clearly 
demonstrated DEX treatment significantly upregulated P-gp mRNA and protein by 5~7 
fold in small intestine but down-regulated in liver by 90% and little or no change in 
kidney, colon or brain microvessels (Mei et al., 2004). However another study in a rat 
endothelial cell line showed even the protein level of P-gp was not changed by DEX, P-
gp function was actually enhanced by a decreased accumulation of vincristine assay 
(Regina et al., 1999). DEX also upregulates MRP2 in both human and rat hepatocytes 
(Courtois et al., 1999; Johnson and Klaassen, 2002; Kast et al., 2002; Kubitz et al., 1999). 
Most recently DEX was shown to induce BCRP in the rat brain microvessels 
(unpublished data). Since CYP3A, P-gp and BCRP are all involved in TPT metabolism 
or elimination, the differential regulatory effects of DEX on these proteins make it hard 
to predict the overall effect of DEX on TPT. On the other hand TPT exposure is deeply 
related to response, a small reduction in TPT systemic exposure may lead to a significant 
loss of antitumor activity (Furman et al., 1996). Recently DEX has also been shown to 
confer resistance to cisplatin and 5-fluorouracil in many of the malignant tumor cells 
(Zhang et al., 2006). Thus it would be of great clinical interest to understand how co-
treatment of dexamethasone affects anti-cancer drug disposition and metabolism. 
 
Different strategies to enhance drug penetration (e.g., ABC transporter 
modulators, anti-angiogenesis therapy) can also be tested in these tumor models. Once 
the pharmacokinetics in tumor tissue can be defined in mouse models, a pharmacokinetic 
model can then be developed to relate the drug exposure in tumor to the exposure in 
plasma. With the model, once an effective therapy is found for a specific tumor in mice, 
it can be translated for human clinical trials. 
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Appendix: Analysis of Topotecan Clearances across BCB or BBB 
 
 
The drug movement across the BBB or BCB can be generalized as CLin (from 
blood to brain) and CLout (from brain to blood) (Hammarlund-Udenaes et al., 1997; 
Wong et al., 1993; Zhuang et al., 2006). Due to the additive property of clearance, CLin 
or CLout can be broken down as follows: 
At BCB of FVB mouse 
 
NONATPinotherATPinPgpBcrpFVBin CLCLCLCLCL ,,, +++=  (Eq. A-1) 
 
NONATPoutotherATPoutFVBout CLCLCL ,,, +=  (Eq. A-2) 
 
At BCB of Bcrp1/Mdr1a/b(-/-) mouse (triple knockout, TKO) 
 
NONATPinotherATPinTKOin CLCLCL ,,, +=   (Eq. A-3) 
 
NONATPoutotherATPoutTKOout CLCLCL ,,, +=  (Eq. A-4) 
 
Subscripts: otherATP-------other than Bcrp1 and P-gp ATP dependent mechanisms 
      NONATP-------All other ATP independent mediated mechanisms 
  
With gefitinib treatment the AUC ratios were determined 1.15 and 1.1 in FVB 
and Bcrp1/Mdr1a/b(-/-) mouse models respectively (Figure 3-4), which were statistically 
the same. According to the relationship of CLin/CLout=AUCu,CSF/AUCu,plasma (Wong et al., 
1993), the following equation can be obtained, 
 
TKOout
TKOin
FVBout
FVBin
CL
CL
CL
CL
,
,
,
,
= , (Eq. A-5) 
 
Substitute each item in equation A-5 with equations A-1 to A-4, we obtained 
 
NONATPoutotherATPout
otherATPinNONATPin
NONATPoutotherATPout
otherATPinNONATPinPgpBcrp
CLCL
CLCL
CLCL
CLCLCLCL
,,
,,
,,
,,
+
+
=
+
+++
 (Eq. A-6) 
 
From equation A-6 and the assumption that gefitinib had the same effect on 
CLotherATP and CLNONATP in FVB as in Bcrp1/Mdr1a/b(-/-) mouse, the following conclusion 
can be made, with gefitinib treatment, at BCB of FVB mouse 
 
0=+ PgpBcrp CLCL  (Eq. A-7) 
 
It suggested gefitinib can fully inhibit Bcrp1 and P-gp functions at BCB. 
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At BBB of FVB mouse 
 
NONATPinFVBin CLCL ,, =  (Eq. A-8) 
 
NONATPoutotherATPoutPgpBcrpFVBout CLCLCLCLCL ,,, +++=  (Eq. A-9) 
 
At BBB of Bcrp1/Mdr1a/b(-/-) mouse (triple knockout, TKO) 
 
NONATPinTKOin CLCL ,, =    (Eq. A-10) 
 
NONATPoutotherATPoutTKOout CLCLCL ,,, +=  (Eq. A-11) 
 
With gefitinib treatment the AUC ratios were determined 0.63 and 0.95 in FVB 
and Bcrp1/Mdr1a/b(-/-) mouse models respectively (Figure 3-4), which were statistically 
different. The following equations can be obtained, 
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,
, < ,  (Eq. A-12) 
 
NONATPoutotherATPout
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 (Eq. A-13) 
 
Then the following conclusion can be made, with gefitinib treatment, at BBB of 
FVB mouse 
 
0>+ PgpBcrp CLCL   (Eq. A-14) 
 
It suggested gefitinib cannot fully inhibit Bcrp1 and P-gp function at BBB. Taken 
together, these results indicated gefitinib had differential regulatory effects on BBB and 
BCB. Probably it is a more universal phenomenon for many other ABC transporter 
modulators than just for gefitinib. Thus it warrants the investigation of specific regulatory 
effects on CNS for the modulators applied to do so even these modulators have shown 
strong effect on other sites (e.g. gastrointestinal tract) (Kuppens et al., 2007).  
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